CURRICULUM VITAE

Name and Contact Details

Professor Andrew Spencer
Department of Clinical Haematology
Alfred Hospital

Qualifications

- Bachelor of Medicine and Surgery - University of Qld, December 1983
- Fellow of the Royal Australian College of Physicians - December 1992
- Fellow of the Royal College of Pathologists of Australasia - December 1992
- Doctorate of Medicine - University of London, January 1998. Thesis - *'Involvement of the B-lymphoid lineage in chronic myeloid leukaemia'*

Other Awards

- Leukaemia Research Fund (UK) Research Fellowship, 1993-1996.
- Leukaemia Research Fund (UK) travel award - EHA course on ' Intensive Sequential Chemotherapy ' - Amsterdam, The Netherlands. 1995.
- British Society of Haematology travel award - 37th Annual American Society of Haematology meeting - Seattle, USA. 1995.
- The Anderson Trust Research Fellowship, 1999-2004
- Premiers Excellency Award, VPHA Awards 2010 – 'Highly Commended'. Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service 'Late Effects Clinic'.
- Gold Winner, VPHA Healthcare Innovation Awards 2012 – 'Innovative ambulatory very-low intensity allogeneic stem cell transplantation program'.
- 'Specialist of the Year', Patients Australia Gala, Melbourne 2025.

Present Appointments

- Principal Specialist and Head, Malignant Haematology, Transplantation and Cellular Therapy Service, Department of Clinical Haematology, Alfred Health. 2007 – present.
- Head, Myeloma Research Group, Australian Centre for Blood Diseases, Monash University. 2001 – present.

- Head, Clinical Research Unit (CRU), Department of Clinical Haematology Alfred Health. 2009 – present.

- Adjunct Professor, Department of Clinical Haematology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University. 2010 – present.

- Affiliate Investigator, Translational Science & Therapeutics Division, Fred Hutchinson Cancer Centre, Seattle. 2021 – present.

Previous Appointments

2013-15	Interim Head of Department (clinical), Department of Clinical Haematology, Alfred Health.
2008-10	Associate Professor, Department of Clinical Haematology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University.
2001-08	Clinical Associate Professor, Department of Medicine, Monash University, Alfred Hospital.
2005-07	Principal Specialist & Head, Clinical Haematology Unit, Southern Health (Monash Medical Centre).
1999-2007	Senior Specialist, Clinical Haematology Unit, Alfred Hospital.
1996–99	Staff Specialist in Haematology, Hunter Area Pathology Service, John Hunter Hospital, Newcastle.
1996-99	Director, Stem Cell Transplantation Service, Hunter Haematology Unit, Newcastle Mater Misericordiae Hospital, Newcastle.
1996-99	Lecturer, Department of Medicine and Health Sciences, University of Newcastle.
1994-96	Honorary Senior Registrar / Research Fellow, LRF Centre for Adult Leukaemia, Department of Haematology, Royal Postgraduate Medical School, London, U.K.
1993-94	Bone Marrow Transplant Co-ordinator/Honorary Senior Registrar, LRF Centre for Adult Leukaemia, Department of Haematology, Royal Postgraduate Medical School, London, U.K.
1993	Locum Director of Haematology, RHH, Hobart.
1992	Registrar in Haematology, RPAH, Sydney.
1990-91	Haematology Pathology Registrar, PAH, Brisbane.
1989	Clinical Haematology and Medical Oncology Registrar, PAH, Brisbane.
1988	Medical Registrar/Liver and Kidney Transplant Unit Registrar, PAH, Brisbane.
1987	Principal House Officer (General Medicine), QE II Hospital, Brisbane.
1986	Senior House Officer, PAH, Brisbane.
1985	Junior House Officer, PAH, Brisbane.
1984	Intern, PAH, Brisbane.

Editorial Responsibilities/Peer Review

- Editorial Board

  Transplantation, 1995 – 2000.
  Bone Marrow Transplantation, 2008 – 2014.
  Cancers – 'Molecular Cancer Biology', 2020 – present
  Annals of Public Health, 2021 – present
  Extracellular Vesicles and Circulating Nucleic Acid, 2022 – present.

- Guest Editor *Frontiers in Oncology – 'Understanding the RNA species in EVs of MM'. 2021*

- Manuscript Review *Transplantation*, 1994 – present.
  Bone Marrow Transplantation, 1994 – present.
  Blood, 1996 - present.
  Internal Medicine Journal, 1999 - present.
  Haematologica, 2002 - present.
  Cancer Research, 2002 - present.
  Clinical Genetics, 2004 – present.
  Pharmacogenetics, 2005 – present.
  Leukemia & Lymphoma, 2006 – present.
  International Journal of Cancer, 2006 – present.
  Experimental Cell Research, 2006 – present.
  British Journal of Haematology, 2006 – present.
  Experimental Hematology, 2006 – present.
  Molecular Cancer Therapeutics, 2007 – present.
  Asia Pacific Journal of Oncology & Hematology, 2008 – present.
  Cancer Letters, 2010 – present.
  Leukemia, 2010 – present.
  PLOS ONE, 2012 – present.
  Anti-Cancer Drugs, 2012 – present.
  Journal of Clinical Oncology, 2021 – present.
  Nature, 2025

- American Society of Hematology

  - Abstract Reviewer/Session Convenor, 48th Annual Meeting 2006 - *Myeloma (Biology and Pathophysiology, excluding Therapy)*
  - Reviewer '*New Drugs in Myeloma'* – ASH Education book, 2009
  - Abstract Reviewer/Session Convenor, 53rd Annual Meeting 2011 - *Myeloma (Biology and Pathophysiology, excluding Therapy)*
  - Abstract Reviewer/Session Convenor, 56th Annual Meeting 2014 - *Myeloma (Therapy, excluding transplantation)*

- European Hematology Association

  - Abstract Reviewer 20th Congress of EHA 2015 – 'Myeloma and other clinical gammopathies – Clinical'
  - Session Chair 20th Congress of EHA 2015 - Simultaneous Session: Multiple myeloma: Clinical studies 1
  - Abstract reviewer 24th Congress of EHA 2019 – 'Myeloma and other clinical gammopathies – Biology & Translational Research'
  - Abstract reviewer EHA2024 – 'Myeloma and other clinical gammopathies – Biomarkers and MRD

- International Myeloma Society

  - Abstract reviewer 21st IMS Annual Meeting, 2024.

- Abstract Reviewer 22nd IMS Annual Meeting, 2025.

- Grant Review Panels

  - Leukaemia Foundation of Australia, 2005 - present
  - NHMRC, 2006 - present
  - Cure Cancer Australia Foundation, 2006 - present
  - Multiple Myeloma Research Foundation (USA), 2006 – present
  - Leukaemia & Lymphoma Research (UK), 2010 – present.
  - International Myeloma Foundation (USA), 2012 – present.
  - Fondation contre le Cancer – Fundamental Research Grants (Belgium), 2014 – present.
  - Cancer Research UK, 2019 – present.
  - Leuka (UK), 2019 – present.
  - Health Research Board (Republic of Ireland), 2023.

- IFM Data Monitoring Committee – Intergroupe Francophone Du Myeloma (IFM) Protocol 2005.02 – 'Relevance of Revlimid maintenance therapy after ASCT in multiple myeloma patients under the age of 65 (A Phase III, multi-centre, randomised, double-blind, placebo-controlled trial). 2009 – 2016.

- Janssen Global Steering Committee - MMY3004 'Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects with Relapsed or Refractory Multiple Myeloma'. 2014 – present.

- Novartis Global Steering Committee – LBH589D2222 'A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different doses of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents'. 2015 – 2020.

- Antegene 017-001 Trial Safety Review Committee – 'A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients with Advanced Solid Tumors and Hematological Malignancies'. 2020 – present.

- Celgene/BMS CC92480 MM 001 Trial Safety Review Committee – 'A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma'. 2021 – present.

- Novartis Global Steering Committee - CPHE885B12201 'A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma'. 2021 – present.

- Janssen Cilag – aMMbition Steering Committee – Ongoing 'Aim for a Cure' trial platform development incorporating CAR-T and TCE therapeutics. 2021 – present.

- IDP Pharma IDP-121-1 CASSANDRA Trial Safety Review Committee – 'A Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies'. 2022- 2025.

Membership of Professional and Learned Societies

- Australian Leukaemia Study Group, 1996 - 2000.
- Australian and New Zealand Lymphoma Group, 1996 - 2000.
- Australian Medical Association, 2002 - 2014.
- European Hematology Association, 2003 – 2014.
- American Society of Clinical Oncology, 2003 – 2015.
- American Association for Cancer Research, 2009 – present.
- Australasian Leukaemia and Lymphoma Group, 2000 – present.
- Fellow of the Royal Australian College of Physicians, 1992 – present.
- Fellow of the Royal College of Pathologists of Australasia, 1992 – present.
- American Society of Hematology, 1995 - present.
- Haematology Society of Australia and New Zealand, 1996 - present.
- Royal Society of Medicine, 2018 – present.

Executive Positions

Previous

- Co-chairperson, HAPS Research Committee, Hunter Area Pathology Service, Hunter Area Health Service, 1997 - 1999.
- Member, Medical Advisory Panel, Leukaemia Foundation of NSW, 1998 - 1999.
- Member, Hunter Area Research Ethics Committee, 1998 - 1999.
- Member, Molecular Haematology Sub-Committee - Quality Assurance Program, Royal Australian College of Pathologists, 1998 – 1999.
- Member, Advisory Panel, Victorian Transplantation and Immunogenetics Service, 1999 – 2004.
- Executive, Australasian Leukaemia and Lymphoma Group (ALLG) 2003 – 2005.
- Member, Scientific and Medical Advisory Committee, Leukaemia Foundation of Victoria (LVF), 2004 – 2005.
- Member, Haematological Tumour Group, (Bayside Health & Southern Health), Southern Melbourne Integrated Cancer Service (SMICS), 2005 – 2006.
- Board of Directors, Leukaemia Foundation of Victoria (LVF), 2005 – 2006.
- Councillor, Haematology Society of Australia and New Zealand (HSANZ) 2005 – 2008.
- Executive and Vice Chairman, ALLG, 2005 – 2008.
- Chair, Myeloma and Low-Grade Lymphoma Disease Sub-committee, Australasian Leukaemia and Lymphoma Group (ALLG) 2003 – 2008.
- Chairman, Australasian Leukaemia and Lymphoma Group (ALLG) 2008.
- Chair, Scientific and Medical Advisory Committee, Leukaemia Foundation of Victoria (LVF), 2005 – 2008
- Vice President, Haematology Society of Australia and New Zealand (HSANZ) 2007 – 2009.
- Chair, ALLG Board of Management Steering Committee, 2008 – 2009.
- Member, National Medical and Scientific Advisory Committee (NMSAC), Leukaemia Foundation of Australia (LFA), 2005 – 2009.
- Member, Steering Committee, Australia & Asia Pacific Clinical Oncology Research Development Workshop 2008 (ACORD), 2007 – 2009.
- Member, Scientific Sub-Committee, Australasian Leukaemia & Lymphoma Group, 1999 - 2009.

- Member, Victorian Cooperative Oncology Group (VCOG) Haemato-Oncology Committee, 2004 – 2010.
- President, Haematology Society of Australia and New Zealand (HSANZ). 2009 – 2011.
- Member, Australian Haemopoietic Progenitor Cell Transplantation (HPCT) Reference Committee, 2009 – 2011.
- Chair, Joint Specialist Advisory Committee (Haematology). 2009 – 2011.
- Director, Board of Management, Australasian Leukaemia & Lymphoma Group, 2010 – 2014.
- Board of Directors, International Myeloma Society (IMS), 2011 - 2015.
- Member, European Myeloma Network Trialist Group Advisory Board, 2009 – 2015.
- Member, European Myeloma Network Trialist Group Early Phase Clinical Trials Sub-committee, 2010 – 2015.
- Chair, Haematological Tumour Group, (Bayside Health & Southern Health), Southern Melbourne Integrated Cancer Service (SMICS), 2006 – 2016.

Current

- Foundation Member, Myeloma Australia, 2002-present.
- Scientific Advisory Board, International Myeloma Foundation (IMF) 2006 – present.
- Member, International Myeloma Working Group (IMWG) 2006 – present.
- Member, Medical and Scientific Advisory Group, Myeloma Australia, 2006 – present.
- Founder and Co-ordinating Principal Investigator bi-national (Australia & New Zealand) Myeloma & Related Diseases Registry (MRDR), 2012 – present.
- Member, IMF Black Swan Research Initiative, 2013 - present.
- Founder and Lead Investigator, Myeloma 1000 - MRDR national biobanking project, 2014 – present.
- Founder and Co-ordinating Principal Investigator, Australasian Myeloma Research Consortium (AMaRC). 2016 – present.
- Founder and Co-ordinating Principal Investigator, Asia Pacific (APAC) Myeloma & Related Diseases Registry (MRDR), 2018 – present.
- Member, TrialHub Advisory Committee, 2020 – present.
- Member, International Myeloma Society Study Summit Group, 2020 – present
- Member, National CAR-T Patient Prioritisation Committee, 2021- present.
- Australian Country Co-ordinating Principal Investigator European Myeloma Network, 2021- present.
- Member, Alfred Health Research Leadership and Governance Committee, 2022 – present.
- Chair, Myeloma Australia MSAG Research Pillar, 2022 – present.
- Member, European Myeloma Network Biobank – Collaboratives Group Committee. 2023 – present.
- Member, International Advisory Committee to Asian Myeloma Network, 2024 – present.
- Foundation Member and Member, Board of Directors, European Myeloma Network, 2025 – present.

Consultancies/Advisory Boards

INDUSTRY:

- **Progen Industries Ltd**

PI88 Expert Advisory Meeting, Brisbane, Nov 2002.

- **Pharmion Pty Ltd**

Multiple Myeloma Education Update, Melbourne/Sydney, Oct 2003.

Australian Advisory Board, **Azacitidine,** July 2005.

- **PacMab Pty Ltd**

Scientific Advisory Boards, 2005 – 2007.

- **Novartis Pharma**

Zometa Think Tank, Monterey, California, June 2002.
Global Advisory Board, **Zometa/Haematology**, Sydney, April 2005.
Exploratory Oncology Development Portfolio Review, New Jersey, October 2005.
Australian Advisory Board, **Zometa**, Sydney, December 2005.
International Steering Committee - Phase II **LBH589 Myeloma** Programme, 2006 – 2015.
Global Advisory Board, **RAD001 Lymphoma** Programme, New Jersey, May 2007.
Global Advisory Board, **LBH589**, Miami, February 2008.
Global Advisory Board, **LBH589/Myeloma**, Washington DC, February 2009.
Australian Advisory Board, **Exjade,** Sydney, March 2009.
Global **LBH589**B2213 Study Steering Committee, December 2009 – present.
Global Advisory Board, **Zometa**, Barcelona, June 2010.
Australian Advisory Board (Chair), **Myeloma,** Melbourne, July 2010.
Global **LBH589** Myelodysplasia Advisory Board, Amsterdam, June 2012.
Europe & Emerging Countries **LBH589** Advisory Board, Milan, June 2014.
LEAD Summit, **Myeloma Pipeline**, Montreal, June 2014.
Chair, Emerging Global Markets, **Relapsed Myeloma** Advisory Board, San Francisco, Dec 2014.
Global Advisory Board, **LBH589 in Myeloma**, Vienna, June 2015.
Global Advisory Board, **LBH589 in Myeloma**, Rome, September 2015.
Global Advisory Board, **New Drug Acquisition Strategy, Myeloma Franchise**, Rome, Sept 2015.
Advisor – Panobinostat PBAC submission, 2015.
Consultant, **Global Myeloma Franchise** – Small molecule inhibitor programme. 2015-2016.
APECHO 2019 Hematology, Orlando, December 2019.

- **Orphan Australia** (Melbourne, Australia), TGA Application Preparation, Dec 2002.

- **Amgen**

Clinical Faculty Meeting, **Pegfilgrastim**, Sydney, Oct 2002.
Australian Advisory Board, **Darbepoetin Alfa**, Melbourne, May 2004.
Australian Advisory Board, **Palifermin**, Sydney, June 2004.
Global Advisory Board, **Denosumab,** Atlanta, Georgia, December 2005.
Australian Advisory Board, **Pegfilgrastim/Palifermin**, Sydney, Sep 2007.
Australian Advisory Board, **Biosimilars,** Melbourne, August 2009.
Scientific Advisory Panel and Co-Chair, Amgen 2006 Clinical Symposium, 2006, 2008 - 2010.
Global **Multiple Myeloma** Research Advisory Board, Atlanta, Georgia, December 2012.
Invited pre-clinical investigator, Onyx Pharmaceuticals - Proteasome Research and Integrative Science for Multiple Myeloma Novel Therapies Program (PRISM NTP). 2014-2015.
Australian **Multiple Myeloma** Advisory Board, Melbourne, February 2016.
Global Oncology Early Pipeline Advisory Board, Madrid, June 2017.
Member, **Myeloma** Executive Advisory Council (EAC), 2019 – ongoing.
Australian **Multiple Myeloma** Virtual Advisory Board, August 2020.

- **Janssen-Cilag**

Bortezomib Reimbursement Advisory Boards, 2004 – present.
Australian Advisory Board, **Haematoloy-Oncology**, 2004.
Global **Daratumumab Myeloma** Advisory Board, Kyoto, April 2013
Global **Daratumumab** Steering Committee, New Orleans, December 2013.
Global **Daratumumab** Steering Committee, San Francisco, December 2014.
Chair, Australian **Multiple Myeloma** Advisory Board, Sydney, August 2015.
Chair, Australian **Multiple Myeloma** Advisory Board, Sydney, December 2016.
Global Hematology Council, **Daratumumab**, Lisbon, April 2017.
Chair, APAC Regional **Myeloma** Advisory board, Hong Kong, July 2017.
Global **Daratumumab** Advisory Board, Dublin, September 2017.
Chair, Australian **Daratumumab** Advisory Board, Melbourne, September 2017.
Global **Multiple Myeloma** Advisory Panel Meeting, Prague, October 2018.
Global **Daratumumab** Advisory Board, Paris, June 2019.
Chair, APAC Regional **Daratumumab** Advisory Board, Hong Kong, July 2019.
Chair, Australian **Daratumumab** Advisory Board, Sydney, October 2019.
Global **Multiple Myeloma** Advisory Panel Meeting, London, November 2019.
Chair, Australian **Multiple Myeloma** Advisory Board, Melbourne, November 2020.
Global Medical Affairs **Daratumumab Multiple Myeloma** Virtual Advisory Board, November 2020.
Global Medical Affairs **'Aim for a Cure'** Virtual Advisory Board, April 2021.
Janssen Australia **Multiple Myeloma CAR-T** Advisory Board, May 2021.
Chair, Janssen Australia **Multiple Myeloma** Advisory Board, October 2021.
Global Medical Affairs **'Aim for a Cure'** Virtual Advisory Board, July 2022.
Global **aMMbition** Steering committee, Virtual meeting, March 2023.
Chair, Asia-Pacific **Multiple Myeloma** Advisory Board, March 2023.
Chair, Janssen Australia **Multiple Myeloma** Advisory Board, April 2023.
Global Bi-specifics **Talquetamab** Advisory Board, Frankfurt, June 2023.
Global **aMMbition** Steering committee, Frankfurt, June 2023.
Chair, Janssen Australia **Multiple Myeloma** Advisory Board, October 2023.
Chair, Asia-Pacific **Multiple Myeloma Novel Assets** Advisory Board, October 2023.
Keynote Speaker, Janssen 'Innovating for patients' company event. November 2023.
Chair, Janssen Australia **Multiple Myeloma** Advisory Board, July 2024.
Chair, Janssen Australia **Multiple Myeloma CAR-T** Advisory Board, Melbourne, March 2025.
Chair, Johnson & Johnson **Multiple Myeloma** Advisory Board, Sydney, December 2025.

- **<u>Celgene Corporation</u>**

International Consultants Meeting, Berlin, August 2006.
Australian Advisory Board, **Revlimid,** 2006 – present.
EU Advisory Board, **Thalidomide,** Florence, March 2008.
Australian Advisory Board, **Myeloma,** Washington DC, February 2009.
Global **Myeloma** Advisory Board, New York, October 2010.
Australian Advisory Board, **Myeloma,** San Diego, December 2012.
Australian Advisory Board, **Myeloma,** Melbourne, July 2012.
Australian Advisory Board, **Myeloma,** Kyoto, April 2013.
Global Advisory Board, **Unmet need in MM and PD-L1 development plan**, Vienna, June 2015.
APAC **Pomalidomide** Advisory Board – Invited speaker, Rome 2015.
Chair, Australian Advisory Board, **Myeloma**, Melbourne, April 2016
Asia-Pacific R & ED Opinion Leader Event, San Diego, December 2016.
Chair, Australian **Myeloma** Advisory Board, Melbourne, August 2017.

Global **Marizomib** Advisory Board, New York, October 2017.
Chair, APAC **Multiple Myeloma** Advisory Board Meeting, Stockholm, June 2018.

- **Schering Plough**

Consultant, **Caelyx** PBAC submission, July 2008.

- **Hospira**

Global Advisory Board, **Nipent**, San Francisco, December 2008.

- **Gilead**

Australia Advisory Board, **Anti-fungal Therapies,** Melbourne, March 2009.
Australia Advisory Board, **Ambisome,** Melbourne, May 2013.

- **MSD**

Myeloma Training Programme, Melbourne, March 2009.
Global **Myeloma** Advisory Board, Vienna, October 2011.
Global **Myeloma** Advisory Board, Barcelona, January 2012.
Global **Multiple Myeloma** Expert Input Forum, San Diego, December 2016

- **GlaxoSmithKline**

Australian Advisory Panel, **Ofatumumab**, Melbourne, July 2009.
Chair, **Belantamab** Advisory Panel, Melbourne, October 2024.
Chair, Global **Myeloma** Strategic Advisory Board, Toronto, September 2025.
Faculty and workshop facilitator, Global DOTS Meeting, Istanbul, November 2025.

- **Pfizer**

Australian Advisory Board, **Eraxis/Vfend,** Sydney, May 2012.
Australian Advisory Board, **Vfend prophylaxis,** Sydney, July 2013.
Australian Advisory Board, **Vfend prophylaxis,** Sydney, November 2014.
Speaker, Haematology Education and Awareness day, Sydney, July 2018.
Global **Multiple Myeloma** Advisory Board, Virtual Forum, May 2020.
Chair, Australian **Multiple Myeloma** Advisory Board, December 2022.
Australian Medical Advisory Board – **Myeloma**, Perth, October 2025.

- **Millenium: The Takeda Oncology Company**

Global **MLN9708 Myeloma** Advisory Board, Kyoto, April 2013.
Global **Myeloma** Registry Proposal Advisory Board, Rome, 2015.
Chair, Australian **Myeloma** Advisory Board, Melbourne, June 2015.
APAC **Ixazomib** Advisory Board – invited speaker, Singapore, July 2015.
Global **Myeloma** Disease Registry Advisory board, Rome, September 2015.
APAC **Ixazomib** Advisory Board – invited speaker, Singapore, March 2016.
Ninlaro (**Ixazomib**) Disease State Training, San Diego, December 2016.
INSIGHT – An international registry of newly diagnosed and relapsed multiple myeloma - Global Steering Committee. 2016 – 2022

- **BMS Australia**

Chair, Australian **Myeloma** Advisory Board, Melbourne, November 2014.
Chair, Australian **Myeloma** Advisory Board, Melbourne, June 2015.

Australian **Myeloma** Virtual Advisory Board, Melbourne, November 2020.

- **Bayer**

Global RA-223 Myeloma Advisory Board, Atlanta, December 2017.

- **Abbvie**

Global Haematology Advisory Board, Frankfurt, May 2018.
Global Haematology Advisory Board, Orlando, December 2019.

- **Servier**

Servier-Novartis Global Multiple Myeloma Advisory Board, San Diego, December 2018.

- **Haemalogix**

Global Advisory Board, San Diego, December 2018.
Global Advisory Board, Amsterdam, June 2019.
Global Advisory Board, Orlando, December 2019.
Global Virtual Advisory Board, June 2020.
Global Virtual Advisory Board, December 2020.
Global Virtual Advisory Board, June 2021

- **Secura Bio**

Global **Panobinostat** Advisory Board, Amsterdam, June 2019.
Global **Panobinostat** Advisory Board, Boston, September 2019.
Global **Panobinostat** Advisory Board, Orlando, December 2019.
Global **Panobinostat** Virtual Advisory Board, June 2020.

.

- **Specialised Therapeutics Australia**

TGA presentation – **Aplidin** review meeting – Canberra, September 2018.

- **TheraMyc**

Global **TM121** Advisory Board, Virtual Forum, June 2020.

- **Roche/Genentech**

Multiple Myeloma Advisory Council Meeting, October 2020.
Myeloma **pBCMA Allo-CAR-T** program Advisory Board, Madrid, June 2024.
Cevostamab Global Advisory Board, Toronto, September 2025

- **Antegene**

Xpovio (Selinexor) Advisory Board, Melbourne, September 2020.

- **Regeneron**

Chair, APAC **REGN5458** Virtual Advisory Board, April 2021.

- **SkyLine**

Chair, Australian MMProfiler Virtual Advisory Board, April 2021.

GOVERNMENT/INDUSTRY:

- Pharmaceutical Benefits Advisory Committee (PBAC) - Imatinib – Cessation of PBS-subsidised treatment in non-responders, March 2004.
- PBAC - Tyrosine Kinase inhibitors in CML, Stakeholder Meeting, May 2008.
- PBAC - Bortezomib Advisory Meeting, June 2009.
- Australian Healthcare Associates (Melbourne, Australia), 2005 – 2006. Expert Medical Advisor - Department of Health and Ageing's independent review of the Australian National Cord Blood Collection Network (NCBCN).
- Department of Health & Aging, Pathology Review Consultation committee (PRCC), 2009 – 2012.
- Victorian Department of Health, Adolescent and Young Adult (AYA) State-Wide Advisory Committee, 2010 – 2013.
- PBAC - Myeloma Therapeutics Stakeholders Meeting, Canberra, May 2018.
- TGA – Aplidin Review Meeting, Canberra, September 2018.
- PBAC - Myeloma Therapeutics Stakeholders Meeting, Melbourne, October 2019.
- Zimmerman Parliamentary Inquiry – 'Inquiry into approval processes for new drugs and novel medical technologies in Australia'. Melbourne, April/May 2021.
- Medicines Australia – PharmAus Event, 'Room for the patient view', expert panel. Canberra, June 2021.
- TGA – Isatuximab Review Meeting, Canberra, August 2021.
- TGA – Selinexor Review Meeting, Canberra, December 2021.
- External review of Haematology Services, Royal Perth Hospital, January – March 2024.
- PBAC - Myeloma Therapeutics Stakeholders Meeting, Melbourne, July 2025.

Teaching and Professional Development

Postgraduate Supervision

- Supervisor *McCaughey Research Scholar*. Dr Ian Kerridge 1999-2000.
  Publication - Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. 'Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk'. British Journal of Haematology 2002; 118: 477-481.
- Supervisor Dr Sharon Avery 2002. *'CXCR4 induced homing and haemopoietic stem cell engraftment'.*
- Supervisor Dr Mark Dawson 2007, Inaugural Roche Australia, Haematology Oncology Targeted Therapies (HOTT) Scholarship – '*Clinical and immunohistochemical features associated with response to Bortezomib in multiple myeloma'.*
- BSc Honours Students – 11 students: 1998 – 2025.
- BMedSci Students – 4 students 2011 – 2025.
- PhD (awarded). Ms Karly Koutrouvelis – *'Mechanisms of TRAIL action and resistance in multiple myeloma'*. 2002 – 2006.
  - *1st Prize, Translational Research Poster, Alfred Hospital Research Week November 2003. Dora Lush NHMRC Biomedical Post-Graduate Scholar, 2004.*
- PhD (awarded). Ms Katherine Monaghan – *'Characteristaion of cell adhesion mediated drug resistance mechanisms in multiple myeloma'.* 2008 – 2012.
  - *MMRF Compound Validation Grant, 2011-2012.*
- PhD (awarded). Ms Cindy Lin – *'The important role of CD45 phosphatase in determining signaling, proliferation and therapeutic drug sensitivities of human myeloma cells'.* 2009 – 2012.
- PhD (awarded). Dr Yianna Savvidou – *'Wnt pathway dysregulation in multiple myeloma'*. 2013 – 2017.

- PhD (awarded). Dr Jay Hocking – *'MEK inhibition as a therapeutic strategy in multiple myeloma'*. 2014 – 2018.
- PhD (awarded). Dr Ioannis Coutsouvelis - 'Optimising the use of supportive care medicines in cancer treatment'. 2014-2022.
- PhD (awarded). Ms Kelsey Man – *'Identifying the biological differences between the CD45 positive and negative populations in multiple myeloma'*. 2016-2019.
- PhD (awarded). Ms Katherine Cummins – *'Modification and targeting of myeloid cell surface antigens to enhance the therapeutic index of CAR-T cells for acute myeloid leukaemia'*. 2017 - 2020
- PhD (awarded). Dr Anna Kalff – *'Multiple Myeloma – Strategies to predict outcome in the era of novel anti-myeloma therapies'.* 2011 – 2019
- PhD (awarded). Dr Krystal Bergin – *'Patterns of care and outcomes for multiple myeloma in Australia'.* 2015-2022.
- PhD (awarded). Dr Antonia Reale – *'Understanding the roles of extra-cellular vesicles in multiple myeloma'*. 2018-2022.
- PhD (awarded). Dr Tricia Wright – *'Developing a model of care for survivorship in haemopoietic stem cell transplant recipients in Victoria'*. 2015 – 2023.
- PhD (awarded). Dr Nicholas Bingham – 'Identification of biological pathways driving disease progression in extramedullary myeloma'. 2019 – 2023.
- PhD candidature. Dr Sueh-li Lim – 'Novel therapeutics in multiple myeloma'. 2021 – ongoing.
- PhD candidature. Dr Daniel Wong – 'Targeting MYC in multiple myeloma'. 2021 – ongoing.
- PhD candidature. Dr Jessie Zhao – 'Examining circulating tumour DNA and circulating tumour cells in high-risk multiple myeloma'. 2022 – ongoing.
- PhD candidature. Dr Miriam Wronski – 'Clinical and Paraclinical Biomarkers to Assist with Diagnosis and Management of Chimeric Antigen Receptor (CAR) T cell Therapy Associated Neurotoxicity'. 2024 – ongoing.
- PhD candidature. Dr Christina Kazzi – 'Neuropsychological outcomes of immune disorders of the central nervous system'. 2024 – ongoing.

<u>Peer Group Educational Activities</u>

- Scientific Organising Committee, Xth International Workshop on Multiple Myeloma 2005.
- Convenor, Alfred Hospital Haematology Forum, 2004 – 2006.
- Scientific Advisory Panel and Chair, Amgen 2006 Clinical Symposium, February 2006.
- Convenor, Victorian Inter-hospital Haematology Educational Meeting Programme 2006 – 2007.
- Haematology Representative, Steering Committee, Australia & Asia Pacific Clinical Oncology Research Development Workshop (ACORD) 2007 – 2010.
- Convenor, Alfred Hospital Clinical Lymphoma Meetings, 2008.
- Convenor, ALLG Myeloma Educational Day, Melbourne, May 2008.
- Scientific Advisory Panel and Co-Chair, Amgen 2006 Clinical Symposium, July 2006.
- Scientific Advisory Panel and Co-Chair, Amgen 2008 Clinical Symposium, July 2008.
- Scientific Advisory Panel and Co-Chair, Amgen 2009 Clinical Symposium, August 2009.
- Scientific Advisory Panel and Co-Chair, Janssen-Cilag 'M^3 Symposium: Managing Multiple Myeloma', Sydney, March 2009.
- Scientific Organising Committee, XIIIth International Workshop on Multiple Myeloma, Paris, 2011.
- Scientific Advisory Panel and Chair, Janssen-Cilag 'M^3 Symposium: Managing Multiple Myeloma', Melbourne, May 2010.
- Scientific Advisory Panel and Co-Chair, Amgen 2010 Clinical Symposium, August 2010.

- Scientific Advisory Committee, Novartis Research & Development Weekend, Melbourne, May 2010.
- Scientific Advisory Panel and Co-Chair, Amgen 2011 Clinical Symposium, May 2011.
- Member, Scientific Committee, HAA-ISHAPD, Sydney, October 2011.
- Scientific Organising Committee, XIVth International Workshop on Multiple Myeloma, Kyoto, 2013.
- Scientific Advisory Panel and Chair, Janssen-Cilag 'M^3 Symposium: Managing Multiple Myeloma', Melbourne, May 2014.
- Chair and Convenor, Asia-Pacific B-Cell Malignancies Educational Symposium, Seoul, Korea, November 2014.
- NSW Cancer Institute eviQ Myeloma Reference Committee, Sydney, March 2015.
- Scientific Organising Committee, XVth International Workshop on Multiple Myeloma, Rome, September 2015.
- Chair and Convenor, Asia-Pacific B-Cell Malignancies Educational Symposium, Hong Kong, October 2015.
- Scientific Advisory Panel and Chair, Janssen-Cilag 'M^3 Symposium: Managing Multiple Myeloma', 2016.
- Chair, Scientific Organising Committee, Inaugural national Myeloma Workshop, September 2016.
- Chair and Convenor, Asia-Pacific B-Cell Malignancies Educational Symposium, Seoul, October 2016.
- Faculty & Session Chair, XVIth International Myeloma Workshop, Delhi, February 2017.
- Chair and Convenor, Asia-Pacific B-Cell Malignancies Educational Symposium, Tokyo, November 2017.
- Scientific Advisory Panel and Chair, Janssen-Cilag 'M^3 Symposium: Managing Multiple Myeloma', 2017.
- Chair and Convenor, Asia-Pacific B-Cell Malignancies Educational Symposium, Shanghai, August 2018.
- Scientific Steering committee, National Myeloma Workshop, Yarra Valley, September 2018.
- Meeting President and Scientific Board Member, 'Extracellular vesicles and their role in patients with multiple myeloma'. SOHO- Society of Hematologic Oncology Meeting. July 2021.
- Scientific Steering committee, National Myeloma Workshop, Yarra Valley, September 2022.
- Scientific Steering committee, Janssen Cilag H3 Symposium, Melbourne, May 2024.

Invited Presentations

State and Interstate

1. *'Development of radiation models to predict leukaemic predisposition'*. Annual HSANZ (Victoria) Scientific Meeting. Kalorama, October 1999.
2. *'New strategies for multiple myeloma'*. Annual HSANZ (Victoria) Scientific Meeting. Kalorama, October 2001.
3. *'Low toxicity approaches to progressive multiple myeloma'*. Haematology Update 2001. Melbourne, October 2001.
4. *'Non-transplant therapy for multiple myeloma'*. Myeloma Victoria, Annual Patient Seminar. Melbourne, March, 2001.
5. *'Transplantation therapy for multiple myeloma'*. Myeloma Victoria, Annual Patient Seminar Melbourne, March, 2002.
6. *'Post-Transplant Lymphoproliferative Disease'*. Melbourne Renal Group, Melbourne, Dec 2002.
7. *'Myeloma bone disease'*. IXth International Myeloma Workshop Review, Melbourne, July 2003.
8. *'Adult leukaemia'*. Anti-Cancer Council of Victoria, Melbourne, October 2003.

9. *'Treatment Options in Multiple Myeloma'*. Myeloma Victoria, Mornington, June 2004.
10. *'Multiple Myeloma'.* Canberra Hospital, Haematology Scientific Meeting. Canberra, November, 2004.
11. *'How should we treat myeloma in 2005'.* Haematology Society of Australia and New Zealand (Western Australian Branch), Perth, May 2005.
12. *'Translational Research in Australia. Can it be done?'* Haematology Society of Australia and New Zealand (Western Australian Branch), Perth, May 2005.
13. *'Current and Future management of myelodysplasia'.* Pharmion MDS Update, Melbourne, March 2007.
14. *'Where to now? Drug evaluation in the post-novel therapy era in myeloma'*. Queensland Branch HSANZ Scientific Meeting, Brisbane, March 2010.
15. *'Multiple Myeloma'*. Tasmanian Haematology Group Scientific Meeting, Hobart, March 2010.
16. *'Cancer registries – Joining the dots: Linking clinical, laboratory and patient populations'.* Monash Comprehensive Cancer Consortium (MCCC) Seminar. Melbourne, April 2012.
17. *'Complete remission and high-risk in Multiple Myeloma'.* Canberra, May 2012.
18. *'CD45 as a model of disease progression in multiple myeloma'*, Adelaide Blood Club, Adelaide, September 2012.
19. *'New targets in multiple myeloma'*, Adelaide Blood Club, Adelaide, September 2012.
20. *'Bortezomib in the front-line treatment of multiple myeloma'.* Velcade National Launch - Perth, September 2012.
21. *'Bortezomib in the front-line treatment of multiple myeloma'.* Velcade National Launch - Melbourne, September 2012.
22. *'Bortezomib in the front-line treatment of multiple myeloma'.* Velcade National Launch - Adelaide, November 2012.
23. *'CD45 and disease progression in multiple myeloma'.* Myeloma Masterclass, Perth, November 2012.
24. *'CD45 as a biomarker of disease progression in myeloma'.* Immunology Seminar, Walter & Eliza Hall Institute, Melbourne, August 2013.
25. *'Multiple myeloma treatment – cumulative dosing and therapeutic sequencing'.* SAMMIG (South Australian Multiple Myeloma Interest Group). Adelaide, February 2015.
26. *'Myeloma Update -2015'.* Perth, July 2015.
27. *'Real world practice and outcome in multiple myeloma'.* Liverpool Hospital, Sydney, February 2019.
28. *'Real world practice and outcome in multiple myeloma'.* Westmead Hospital, Sydney, February 2019.
29. *'Treatment of early relapse patients in multiple myeloma'* – Speaker Tour. Adelaide, Canberra, Perth, Brisbane, Newcastle, Sydney. March – June, 2024.
30. *'EHA 2024 – Update and evaluation'.* Royal Prince Alfred Hospital, Sydney, August 2024.

National

1. *'Multiple Myeloma'*. Australian Institute of Laboratory Scientists Forum. Melbourne, August 2002.
2. *'MM6 Trial Update'*. Multiple Myeloma Update 2003. Melbourne and Sydney, 8th and 9th October 2003.
3. *'Autologous stem cell transplantation for multiple myeloma'.* Plenary Session Annual Scientific Meeting of the Haematology Society of Australia and New Zealand. Melbourne, Australia, October 2004.
4. *'Standard Therapy for Multiple Myeloma'*. Australian Myeloma Foundation. Melbourne, April 2005.
5. *'Novel Approaches in multiple myeloma'.* Novartis Oncology Australia – Research and Development Symposium. Sydney, June 2005.
6. *'Prolonging Remission in Follicular Lymphoma – Autologous Stem Cell Transplantation'.* Haematology-Oncology Targeted Therapies Symposium. Sydney, July 2005.
7. *'Dose escalation strategies in multiple myeloma'.* The 2006 Amgen Clinical Symposium. Melbourne, February 2006.

8. *'Myeloma as a testing ground for novel compounds'.* Novartis Oncology Australia – Research and Development Symposium. Melbourne, August 2007.
9. *'Optimising response to front-line ASCT in newly diagnosed multiple myeloma'.* M3 Symposium: Managing Multiple Myeloma. Sydney, March 2008.
10. *'Transplantation in multiple myeloma', ALLG Transplantation Symposium*. Melbourne, May 2008.
11. '*Pitfalls in pre*-clinical evaluation of myeloma therapeutics', M3 Symposium: Managing Multiple Myeloma. Sydney, May 2009.
12. *'The new novel therapies'*, M3 Symposium: Managing Multiple Myeloma. Sydney, May *2009.*
13. '*Exploring post-transplant strategies to prolong survival',* Future Directions Symposium – The evolving World of Multiple Myeloma, Melbourne, July 2009.
14. *'Australian Studies in Multiple Myeloma'.* HAA 2009 (HSANZ, ANZSBT, ASTH Annual Scientific Meeting), Adelaide, October 2009.
15. '*Lessons learned from treating with histone deacetylase inhibitors.* Novartis Oncology Australia – Research and Development Symposium. Melbourne, May 2010.
16. *'Is there a need for ongoing suppressive therapy in multiple myeloma'.* M3 Symposium: Managing Multiple Myeloma. Melbourne, May *2009.*
17. '*Measures of MRD in multiple myeloma'.* Celgene Australasian National Think Tank. Melbourne, September 2010.
18. '*Evaluation of experimental models of myeloma'.* HAA 2010 (HSANZ, ANZSBT, ASTH Annual Scientific Meeting), Auckland, New Zealand, October 2010.
19. '*Myeloma related testing'.* RCPA Pathology Update 2011. Melbourne, March 2011.
20. '*Novel combinations for emerging pathways in multiple myeloma'.* Novartis Oncology Oceania, R & D Symposium. Melbourne, May 2012.
21. '*Defining complete remission and minimal residual disease in multiple myeloma.* M3 Symposium: Managing Multiple Myeloma. Sydney, May *2012.*
22. '*Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease – a post-hoc analysis of the effect of denosumab treatment'.* Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane, August 2012.
23. '*CD45 as a biomarker of disease progression in multiple myeloma'.* Royal Prince Alfred Hospital 2013 Symposia, Sydney, August 2013.
24. '*Establishment of an outpatient-based ambulatory allograft programme'.* Royal Prince Alfred Hospital 2013 Symposia. Sydney, August 2013.
25. '*Targeting pathways in multiple myeloma'.* Novartis GET Weekend Meeting. Sydney, July 2014.
26. '*Optimising front-line therapy for newly diagnosed myeloma – An Australian perspective'.* New Frontiers in Therapeutic Options. Perth, October 2014.
27. '*Bone turnover marker levels and clinical outcomes in advanced cancer patients treated with antiresorptive bone therapies'.* Medical Oncology Group of Australia Annual Scientific Meeting, Hobart, August 2015.
28. '*Autologous stem cell transplantation followed by an outpatient-based non-myeloablative allogeneic (NMA) stem cell transplant (auto-allo) for biologically adverse multiple myeloma'.* Proffered paper - Combined HSANZ/ASTH Presidential Symposium, HAA Annual Scientific Meeting, Adelaide, October 2015.
29. '*Genetics and epigenetics in multiple myeloma'.* Plenary Speaker, HAA Annual Scientific Meeting, Melbourne, November 2016.
30. '*Potential of liquid biopsies in multiple myeloma.* M3 Symposium: Managing Multiple Myeloma. Melbourne, August 2017.
31. '*Multiple Myeloma – A disease in Evolution'.* Plenary Speaker, New Directions in Leukaemia Research, Brisbane, March 2018.

32. *'Navigating the upfront treatment and early first relapses in MM in Australia: Current status and future directions'.* H^3 Symposium, Sydney, August 2018.
33. *'Understanding real world frontline therapy for multiple myeloma in Australia'.* Meeting series – Melbourne, Brisbane, Perth, Sydney, Adelaide, June – August 2018.
34. *'Optimising relapsed and refractory disease treatment – Australian context'.* Myeloma Special Practice Network Seminar, Adelaide, August 2018.
35. *'Myeloma and Related diseases Registry – Australian/New Zealand'.* Myeloma Special Practice Network Seminar, Adelaide, August 2018.
36. *'Utilising the Myeloma and Related Diseases (MRDR) as a platform for the Australasian Myeloma Research Consortium (AMaRC)'.* Registry-Randomised Trials Colloquium, Adelaide February 2019.
37. *'DNA-repair gene mutations are prevalent in circulating tumour DNA from advanced multiple myeloma patients'*. BLOOD, Perth October 2019.
38. *'Utilisation of liquid biopsies in 'functional' high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity'*. BLOOD, Perth October 2019.
39. *'ALLG MM17 Trial: A response adaptive salvage strategy with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Multiple Myeloma patients failing front-line Bortezomib'*. BLOOD, Perth October 2019.
40. *'Efficacy and Safety of Daratumumab / Bortezomib / Dexamethasone (D-Vd) Versus Bortezomib / Dexamethasone (Vd) in First Relapse Patients With Multiple Myeloma: Two-Year Update of CASTOR'*. BLOOD, Perth October 2019.
41. *'Improving myeloma outcomes in the real world: The role of the Myeloma and Related Diseases Registry (MRDR)'*. National Oncology Alliance – Rare Cancers Australia Virtual Workshop, May 2020.
42. *'EHA25 Virtual Webinar'.* The Limbic. July 2020.
43. *'Post ASCO-EHA highlights'.* Roche Webinar, July 2020.
44. *'Early disease progression identifies an ultra-high-risk sub-group of newly diagnosed multiple myeloma – A Myeloma and Related Diseases Registry (MRDR) analysis'.* 3rd National Myeloma Workshop, Melbourne, September 2020.
45. *'Relapsed Multiple Myeloma'.* Janssen Cilag Multiple Myeloma Webinar, October 2020.
46. *'Minimal residual disease in multiple myeloma'.* ALLG Myeloma Workshop Webinar, October 2020.
47. *'Evolution of risk stratification in multiple myeloma'.* New Frontiers in Haematology Webinar, November 2020.
48. *'Treatment of patients with DVd in the clinical trial setting and expectations for the real-world'.* Darzalex launch meeting, Melbourne, April 2021.
49. *'Transplantation in multiple myeloma'.* Centre for Blood Transplant and Cellular Therapies, Melbourne, April 2021.
50. *'Interrogating circulating nucleic acids to characterize multiple myeloma'.* New Directions in Leukaemia Research. Brisbane, May 2022.
51. *'Liquid biopsies for liquid tumours'.* 8th Thomas Ashworth CTC & Liquid Biopsy Symposium. Sydney, October 2022.
52. *'ctDNA as a guide to treatment in multiple myeloma'.* 4th National Myeloma Workshop. Melbourne, October 2022.
53. *'Mass spectrometry: Preliminary Australian Data.* 4th National Myeloma Workshop. Melbourne, October 2022.
54. *'New insights and opportunities in relapsed myeloma'.* BMS New Frontiers in Haematology. Melbourne, November 2022.
55. *'EHA Multiple Myeloma review'.* The Limbic. Melbourne, June 2023.
56. *'CAR-T in multiple Myeloma'.* Myeloma Australia Educational Event, Darwin, October 2023.
57. *'Risk assessment and risk adapted therapy'.* Horizons 24. Sydney, August 2024.
58. *'Myeloma and Related diseases Registry – An update'.* 5th National Myeloma Workshop. Melbourne,

August 2024.

59. '*Emerging approaches for peripheral blood disease monitoring for multiple myeloma'.* Binding Site Extent launch meeting. Sydney, October 2024.

60. '*Ageism in multiple myeloma treatment'.* BLOOD 2024 Meeting. Brisbane, October 2024.

61. '*A decade of data: Myeloma & Related Diseases Registry.* HSANZ Nurses Day. Sydney, November 2024.

62. '*Mass spectrometry in multiple myeloma'.* Path Update. Melbourne, February 2025.

63. '*Multiple myeloma treatment in the elderly'.* ANZ TCT Annual Meeting. Gold Coast, August 2025.

64. '*Regional trends in first-line myeloma treatment: Real-world results from the ANZ and APAC MRDR'.* BLOOD 25 Meeting. Perth, October 2025.

International

1. '*Graft versus host disease – Diagnosis and management*'. Transplantation Society of Australia and New Zealand. Melbourne, Australia, April 2001.

2. '*Feasibility of thalidomide and zoledronic acid maintenance therapy post-stem cell transplant for patients with multiple myeloma'.* Novartis Asia-Pacific Oncology Summit. Hainen, People's Republic of China, 20th – 22nd February 2004.

3. '*Multiple myeloma/non-Hodgkin's lymphoma'*. New Zealand Haematology Weekend, Queenstown, New Zealand, September 2004.

4. '*Thalidomide as maintenance therapy in Multiple Myeloma'.* Thalidomide – Key Opinion Leaders. Gold Coast, Australia, October 2004.

5. '*Maintenance therapies for non-Hodgkins Lymphoma following ASCT'.* 9th Korean Society of Hematopoeitic Stem Cell Transplantation (KSHSCT) Winter Congress. Muju, South Korea, February 2005.

6. '*Zoledronic Acid:* Safety and pharmacokinetic analysis of the ALLG MM6 trial. 10th International Myeloma Workshop. Sydney, Australia, April 2005.

7. '*Maintenance Therapy Approaches for Multiple Myeloma'* 10th Congress of the European Hematology Association (EHA). Stockholm, Sweden, June 2005.

8. '*Dose selection for thalidomide therapy of multiple myeloma'.* Thalidomide – Key Opinion Leaders. Perth, Australia, August 2005.

9. '*Gemcitabine-based approaches to peripheral T-cell lymphoma'.* International T-cell lymphoma workshop. Chicago, USA, July 2006.

10. '*Pre-clinical evaluation of novel therapies for multiple myeloma'.* INSERM Institute de Biologie. Nantes, France, November 2006.

11. '*Maintenance therapy with thalidomide post-ASCT'*. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). Lyon, France, April 2007.

12. *'Is the maintenance benefit with novel agents post autologous transplant real or illusory?'* Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). Florence, Italy, March 2008.

13. '*Translational approaches to myeloma drug development'.* Asia Pacific Translational Medicine Workshop, Shanghai, China, March 2008.

14. '*Translational Research'.* Australia & Asia Pacific Clinical Oncology Research Development Workshop (ACORD). Sunshine Coast, Australia, September 2008.

15. '*Multiple Myeloma – State of the Art'.* 50th American Society of Hematology (ASH) Annual Meeting and Exposition. San Francisco, USA, December 2008.

16. '*Epigenetic drugs: Chromatin remodelling or DNA damage and repair'.* Clinical Translation of Epigenetics in Cancer Therapy. Coral Gables, Florida, USA, January 2009.

17. *'Vidaza: Laboratory and clinical applications'.* CpGEMM Think Tank, Washington DC, USA, February 2009.
18. *'Where to now? Drug evaluation in the post-novel therapy era in myeloma'.* New Zealand HSANZ Scientific Meeting. Auckland, March 2010.
19. *'The Modern Approach to Multiple Myeloma'.* World Congress of Internal Medicine. Melbourne, March 2010.
20. *'Pre-clinical evaluation and novel therapeutics'.* 13th International Myeloma Workshop. Paris, May 2011.
21. *'Translational research and clinical development of FGFR inhibitors in haematological malignancies'.* Novartis Oncology Asia Pacific Summit. Singapore, July 2011.
22. *'Consolidation approaches and pre-clinical evaluation of future therapeutics in multiple myeloma'.* 73rd Annual Meeting of the Japanese Society of Hematology Annual Meeting. Nagoya, Japan, October 2011.
23. *'Treatment of multiple myeloma in the era of novel agents'.* 73rd Annual Meeting of the Japanese Society of Hematology Annual Meeting. Nagoya, Japan, October 2011.
24. *'Salvage and Phase 1 protocols'.* 5th Trialist Forum European Myeloma Network. Baveno, Italy, May 2012.
25. *'What is the optimal duration of maintenance therapy?'* 14th International Myeloma Workshop. Kyoto, Japan, April 2013.
26. *'The upfront treatment in young myeloma patients: what maintenance therapy?'* Multiple myeloma and related malignancies. Bari, Italy, November 2013.
27. *'Overview of the myeloma research programme at Alfred Health'.* PRISM NTP Investigator meeting. New York, USA, May 2014.
28. *'Evaluation of circulating free nucleic acids in myeloma to monitor disease progression and response to treatment'.* International Myeloma Foundation, Black Swan Research Initiative investigators meeting. Milan, Italy, June 2014.
29. *'Multiple Myeloma – Individualised therapy with the advent of new therapeutic options'.* 2nd Academy of Clinical Experts (ACE) Meeting. Mumbai, India July 2014.
30. *'Multiple Myeloma – Inching toward cure'.* 2nd Academy of Clinical Experts (ACE) Meeting. Mumbai, India July 2014.
31. *'Management of elderly patients with multiple myeloma'.* Asia Pacific B Cell Malignancies Meeting an initiative of the Academy for Cancer Education (ACE), Seoul, Korea, November 2014.
32. *'Circulating free nucleic acids in myeloma'.* International Myeloma Foundation, Black Swan Research Initiative investigators meeting. San Francisco, USA, December 2014.
33. *'Pre-clinical /clinical data on MDX1097 (KappaMab) – Targeting kappa myeloma antigen'.* First Annual Immuno-Oncology in Myeloma Scientific Workshop. Houston, Texas, May 2015.
34. *'Circulating free nucleic acids in myeloma'.* International Myeloma Foundation, Black Swan Research Initiative investigators meeting. Vienna, Austria, June 2015.
35. *'Understanding the role of epigenetics in the pathogenesis and treatment of multiple myeloma'*. 20th Congress of EHA. Vienna, June 2015.
36. *'Phase 1, multicentre, open-label, dose-escalation, combination study of pomalidomide (POM), marizomib (MRZ), and dexamethasone (Lo-Dex) in patients with relapsed and refractory multiple myeloma'.* Plenary presentation as highest scoring clinical abstract. 15th International Myeloma Workshop. Rome, September 2015.
37. *'Epigenetics - biology in multiple myeloma'.* 15th International Myeloma Workshop. Rome, September 2015.
38. *'Targeting oncogenic pathways in multiple myeloma – inhibition of AKT and MEK'.* 15th International Myeloma Workshop. Rome, September 2015.

39. *'New diagnostic criteria for multiple myeloma'.* 2nd Asia Pacific B Cell Malignancies Meeting an initiative of the Academy for Cancer Education (ACE), Hong Kong, October 2015.
40. *'Future potential therapeutics for multiple myeloma'.* Korean Hematology Society Annual Spring Meeting, Deang, South Korea, November 2015.
41. *'Circulating free nucleic acids in myeloma'.* International Myeloma Foundation, Black Swan Research Initiative investigators meeting. Orlando, Florida, December 2015.
42. *'New drugs and new targets in multiple myeloma*. Japanese Myeloma Society Annual meeting, Tokyo, May 2016.
43. *'Minimal residual disease in multiple myeloma'*. 2016 Myeloma Summit. Beijing, China. May 2016.
44. *'Management of MGUS and smouldering multiple myeloma'*. 2016 Myeloma Summit. Beijing, China. May 2016.
45. *'Rationale for HDAC inhibition in multiple myeloma and clinical experience with pan-HDAC inhibitors'*. 21st Congress of EHA, Copenhagen, June 2016. Session Chair and speaker.
46. *'Role of epigenetics in the pathogenesis and treatment of multiple myeloma'*. Novartis Hematology Forum, Tokyo, July 2016.
47. *'Aiming for maximal benefit in front-line myeloma treatment'.* 3rd Asia Pacific B-cell malignancies meeting, Seoul, August 2016.
48. *'Role of allogeneic stem cell transplantation in the era of novel therapeutics for multiple myeloma'*. Singapore General Hospital, Singapore, September 2016.
49. *'Outcomes of an ambulatory allografting programme for adverse risk multiple myeloma*'. APBMT Annual Congress, Singapore, October 2016.
50. *'New technologies and new molecules in multiple myeloma'*. Carioca Multiple Myeloma Symposium, Rio de Janeiro, October 2016.
51. *'Mutational characterisation of multiple myeloma by investigation of circulating free DNA'*. 6th Heidelberg Myeloma Workshop, Heidelberg, May 2017.
52. *'cfDNA and non-invasive genomics; Are they ready for prime-time'*. MYELOMA 2017, Edinburgh, October 2017.
53. *'Novel agents for multiple myeloma in 2017'*. Myeloma Tutorial, Taipei, November 2017.
54. *'Managing patients at first relapse.* 4th Asia Pacific B-cell Malignancies Meeting, Tokyo, November 2017.
55. *'Clinical update on daratumumab'.* Meet the Expert, Kobe, November 2017.
56. *'Update on cfDNA studies in multiple myeloma'.* IMF Black Swan Research Initiative, Atlanta, December 2017.
57. *'Functional Genomics in Multiple, Myeloma'.* Annual Scientific Meeting, Hong Kong Society of Haematology. Hong Kong, April 2018.
58. *'Shifting treatment paradigms in multiple myeloma'.* Hematology Society Annual Congress, Taipei, Taiwan, April 2018.
59. *'Optimising induction regimens in transplant eligible front-line multiple myeloma'.* Celgene Asia Pacific Multiple Myeloma Preceptorship. Seoul, Korea, May 2018.
60. *'Tandem Transplants in multiple myeloma'.* Celgene Asia Pacific Multiple Myeloma Preceptorship. Seoul, Korea, May 2018.
61. *'The role of allograft in the treatment of multiple myeloma'.* Celgene Asia Pacific Multiple Myeloma Preceptorship. Seoul, Korea, May 2018.
62. *'Next Generation Flow Cytometry for MRD evaluation in multiple myeloma'.* Celgene Asia Pacific Multiple Myeloma Preceptorship. Seoul, Korea, May 2018.
63. *'Sequencing novel agents at first relapse'.* 5th Asia Pacific B-cell Malignancies Meeting, Shanghai, August 2018.

64. *'Real world data in newly diagnosed multiple myeloma – ANZ Registry'.* 5th Asia Pacific B-cell Malignancies Meeting, Shanghai, August 2018.
65. *'Long-term safety of daratumumab plus bortezomib and dexamethasone (D-Vd) in RRMM: CASTOR'.* 80th Annual Meeting of the Japanese Society of Hematology. Osaka, Japan, October 2018.
66. *'Real world practice and strategies to improve outcome in multiple myeloma'.* Onco-Summit. Seoul, Korea, January 2019.
67. *'Denosumab in the bone health management of patient with multiple myeloma'.* 47th Annual Scientific Meeting of the Hong Kong Society of Haematology. Hong Kong, March 2019.
68. *'Advances in relapse and bone management in multiple myeloma'.* 47th Annual Scientific Meeting of the Hong Kong Society of Haematology. Hong Kong, March 2019.
69. *'Emerging treatment options for elderly patients with multiple myeloma'.* 44th Annual Meeting of the Japanese Society of Myeloma. Nagoya, Japan, May 2019.
70. *'Liquid biopsy in multiple myeloma'.* 44th Annual Meeting of the Japanese Society of Myeloma. Nagoya, Japan, May 2019.
71. *'Treatment of relapsed or refractory multiple myeloma'.* Multiple Myeloma Meet the Expert, Chiba, Japan, May 2019.
72. *'Circulating tumor DNA: Applications in Myeloma'.* Controversies in Multiple Myeloma (COMy). Paris, May 2019.
73. *'Australia and New Zealand – Clinical Trials in Progress'.* XVIIth International Myeloma Workshop. Boston, September 2019.
74. *'Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity'.* XVIIth International Myeloma Workshop. Boston, September 2019.
75. *'A phase 1, first-in-human study of AMG176, a selective MCL-1 inhibitor, in patients with relapsed or refractory multiple myeloma'.* XVIIth International Myeloma Workshop. Boston, September 2019.
76. *'Improving outcomes in the real-world'.* XVIIth International Myeloma Workshop. Boston, September 2019.
77. *'Therapeutic strategies for RRMM in the era of novel therapies'.* 5th MM Forum of Standardised Diagnosis and Treatment. Guangzhou, China, September 2019.
78. *'Real world outcomes for newly diagnosed patients with functional high-risk myeloma – A Myeloma and Related Diseases Registry (MRDR) analysis'.* 61st American Society of Hematology Annual Meeting. Orlando, December 2019.
79. *'Exploratory evaluation of CyTOF populations during myeloma treatment'.* Scientific Workshop on Immune Profiling and Minimal Residual Disease. 61st American Society of Hematology Annual Meeting. Orlando, December 2019.
80. *'Exploring spatial heterogeneity in multiple Myeloma'.* Fred Hutchinson Cancer Research Centre. Seattle, January 2020.
81. *'Circulating tumor DNA: Applications in Myeloma'.* Controversies in Multiple Myeloma (COMy). Paris, May 2020.
82. *'How I treat plasma cell leukaemia'.* Malaysian Society of Haematology Annual General Meeting, Kuala Lumpur, September 2020.
83. *'Minimal residual disease in multiple myeloma.* Malaysian Society of Haematology Annual General Meeting, Kuala Lumpur, September 2020.
84. *'Bone complication management in multiple myeloma.* Malaysian Society of Haematology Annual General Meeting, Kuala Lumpur, September 2020.
85. *'Lenalidomide as the foundation for first-line therapy in multiple myeloma'.* Thailand society of Haematology Annual Scientific Meeting, Bangkok, September 2020.

86. *'DNA repair gene mutations in multiple myeloma'.* Multiple Myeloma and Related Malignancies – 5th Edition. Bari, Italy, November 2020.
87. *'Multiple Myeloma in 2020'.* Opinions in Multiple Myeloma and Amyloidosis: An interactive Global Virtual Summit. November 2020.
88. *'Liquid biopsy in Multiple Myeloma'.* Extracellular vesicles and their role in patients with multiple myeloma, SOHO- Society of Hematologic Oncology Meeting. July 2021.
89. *'Improving myeloma outcomes in the real world: the role of the myeloma and related diseases registry'.* Controversies in Multiple Myeloma (COMy). Paris, France, March 2022.
90. *'Treatment sequencing for multiple myeloma and the position of daratumumab'.* 9th Janssen Hematological Malignancies Summit. Beijing, China, August 2022.
91. *'What's new in transcription factors in multiple myeloma'.* Multiple Myeloma and Related Malignancies - 6th Edition. Bari, Italy, November 2022.
92. *'A Phase 2 trial of an immunotherapeutic salvage approach for patients failing front-line bortezomib-based induction'.* CD38 in basic science and clinical practice. Bergamo, Italy, July 2023.
93. *'Non-invasive screening and targeted panels'.* International Myeloma Society, Genomics and Precision Medicine Meeting. Barcelona, July 2023.
94. *'Measurable residual disease in multiple myeloma'*. Japanese Society of Hematology. Tsukuba, Japan, July 2023
95. *'Emerging strategies for blood-based monitoring in multiple myeloma'*. Japanese Society of Hematology. Tsukuba, Japan, July 2023.
96. *'Blood-based monitoring in multiple myeloma'*. Hematology Society of Taiwan. Taipei, Taiwan, October 2023.
97. *'Liquid biopsy in multiple myeloma – BSRI Collaboration'*. IMF Black Swan Research Initiative, San Diego, December 2023.
98. *'How new data may (or may not) change practice in Multiple Myeloma'*. Janssen HME AP Multiple Myeloma Webinar, April 2024.
99. *'Lessons from the MRDR – Utilising real-world evidence to enhance outcomes'.* NZ Myeloma Summit, August 2024. Queenstown, New Zealand.
100. *'New insights into high-risk myeloma'.* NZ Myeloma Summit, August 2024. Queenstown, New Zealand.
101. *'The emerging therapeutic landscape of multiple myeloma'.* BMS Haematology Summit. Taiwan, September 2024.
102. *'MRD driven multiple myeloma treatment'.* TCVGH International Medication Conference. Taichung, Taiwan, October 2024.
103. *'Update in liquid biopsies in MM'.* Black Swan Research Initiative. San Diego, USA, December 2024.
104. *'Genetic assessment for all patients? (EMD PCL CTC and other factors vs Genetic) – YES'.* 6th European Myeloma Network Meeting. Athens, April 2025.
105. *'Circulating tumour cells and ctDNA'.* 11th World Congress on Controversies in multiple Myeloma (COMy). Paris, May 2025.
106. *'Optimising therapies for elderly myeloma patients'.* Canadian Myeloma Research Group (CMRG) – Creating Strong Partnerships to Optimize Investigator-initiated Studies. Toronto, Canada, September 2025.
107. *'Blood based diagnosis and monitoring'*. IMF Asian Myeloma Network Summit. Nagoya, Japan, October 2025.
108. *'ctDNA Update'.* Black Swan Research Initiative. Orlando, USA, December 2025

RESEARCH FUNDING

Competitive Grants

1. 1994. Leukaemia Research Fund Fellowship (UK). *'Involvement of the B-lymphoid lineage in chronic myeloid leukaemia'* - **$150,000.**
2. 1997. University of Newcastle, Medical Faculty equipment grant. **$11,800.**
3. 1997. Hunter Area Pathology Service Research Committee grant. '*Flow cytometric and molecular detection and characterisation of tumour cells in patients undergoing treatment for multiple myeloma'*. **$10,000.**
4. 1998. Leo and Jenny Leukaemia and Cancer Foundation. *'A comparative analysis of induced mutational spectra in normal individuals and chronic phase chronic myeloid leukaemia (CML) sufferers'*. **$49,810.**
5. 1998. Hunter Area Pathology Service Research Committee grant. *'Karyotypic and proto-oncogenic lesions identifiable in patients with multiple myeloma (MM) and monoclonal gammopathy of uncertain significance (MGUS)'*. **$8,600**.
6. 1999. Royal Australasian College of Physicians / McCaughey Research Scholarship. '*Heritable metabolic enzyme polymorphisms and lymphoma susceptibility'*. **$25,000.** (co-investigator – I.Kerridge).
7. 1999. Margaret Mitchell Research Grant. *'Development of a novel molecular technique for the detection of chromosomal translocations in B-cell malignancies'*. **$7,500**.
8. 1999. Consultative Committee on Diagnostic Imaging Research in Diagnostic Imaging/Nuclear Medicine Grant. 'The utility of chest radiography in patients with febrile neutropenia'. **$55,018.**
9. 2002. Margaret Mitchell Research Grant. *'Genetic differences in carcinogen metabolising enzymes and increased susceptibility to multiple myeloma'*. **$9,910**.
10. 2002. Leukaemia Foundation of Victoria. '*Establishment of a human multiple myeloma implant model'.* **$33,120.**
11. 2006–2010. NHMRC Enabling Grant, No. 389202. *'Australasian Leukaemia and Lymphoma Group (ALLG) National Leukaemia and Lymphoma Tissue Bank (NLLTB)'*. **$1,500,000.**
12. 2010-2012. Victorian Cancer Agency (VCA). *'Epigenetics and Cancer Therapy'*. **$2,200,000**
13. 2011-2012. Multiple Myeloma Research Foundation (MMRF) (USA) Novel Combinations and Novel Compounds Award – '*Targeted inhibition of JAK-STAT signaling to modify MM drug resistance'*. **$200,000**
14. 2012. Snowdome Foundation. Clinical Fellowship in Epigenetic Therapies. **$109,000**
15. 2014-2015. International Myeloma Foundation (IMF) (USA). *'A pilot study to identify circulating biomarkers in the peripheral blood of multiple myeloma patients to monitor disease progression and response to treatment'*. **US$270,000 (AUS$360,000)**
16. 2014-2017. Victorian Cancer Agency (VCA). *'Victorian Epigenetics Group (VEG): A collaboration for personalised epigenetic cancer therapy through pre-clinical evaluation, novel biomarker development and early phase clinical trials of new drugs'.* **$419,500**
17. 2014-2015. Proteasome Research and Integrative Science for Multiple Myeloma (Novel Therapies Programme). '*Pre-clinical evaluation of carfilzomib in combination with MEK inhibition for multiple myeloma'.* **US$116,000 (AUS$155,000)**
18. 2014-2015. Snowdome Foundation. *'Identifying cancer biomarkers for predicting response to histone deacetylase inhibitor +/- proteasome inhibitor therapy in myeloma'.* **$86,000.**
19. 2016-2018. International Myeloma Foundation (IMF) (USA). *'Correlative study programme for the ALLG MM17 trial'*. **US$370,000 (AUS$493,000)**
20. 2016-2017. Australian Cancer Research Fund – '*Establishment of a Blood Cancer Therapeutics Centre'*. **$1,200,000**

21. 2017-2018. International Myeloma Foundation (IMF) (USA). *'Investigating the utility of circulating cell-free RNA as a non-invasive therapeutic biomarker for monitoring disease progression in MM'* **US$222,324 (AUS$295,700)**
22. 2017-2018. Medical Research Futures Fund (MRFF). *'The Myeloma and Related Diseases Registry (MRDR) Clinical Trials Platform'.* **$200,991**
23. 2016-2019. Victorian Cancer Agency (VCA*). 'Augmented immune targeting of a myeloma-specific tumour antigen'*. **$1,974,342**
24. 2017-2019. NHMRC. APP1127387 – *'Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma'*. **$497,857**
25. 2017-2019. Equity Trustees. *'Exploratory analysis of circulating free RNA as a non-invasive biomarker in multiple myeloma utilizing the MRDR and AMARC'*. **$136,800.**
26. 2018-2021. NHMRC APP1142184 – *'Analysis of circulating tumour DNA for mutational characterization and tracking disease progression in multiple myeloma'*. **$908,000**
27. 2018 - 2020. International Myeloma Foundation (IMF) (USA*). 'Analysis of next generation sequencing data generated from liquid biopsy projects (ALLG MM17 trial and cfRNA in multiple myeloma)'.* **US$224,946 (AUS$308,614)**
28. 2019 – 2022. NHMRC APP1162954 – *'A new therapeutic target in proteasome inhibitor resistant multiple myeloma'.* **$676,589**
29. 2020 - 2023. Medical Research Futures Fund (MRFF) 1200706. *'Epidemiological modelling to deliver better care for Australian patients with myeloma'.* **$459,847**

Current Competitive Grants

30. 2019 - 2025. Medical Research Futures Fund (MRFF). *'Frailty-stratified, randomized controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - FRAIL-M study'.* **$1,680,000**
31. 2020-2024**.** NIH Cancer Moonshot/Immuno-oncology Translational Network**.** *'Optimizing myeloma specific immunity after autologous stem cell transplantation'.* **US$4,200,000 (AUS$6,250,000)**
32. 2021 – 2024. Australian Data Research Commons DP708. 'A national transfusion data asset for Australia'. **$499,000**
33. 2021 - 2026. NHMRC APP2006451 *'Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial'.* **$2,490,421**
34. 2022 – 2026. Medical Research Futures Fund (MRFF) 2014646. More efficient delivery of high-cost standard of care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial. **$1,680,000**
35. 2024-2028. Medical Research Futures Fund (MRFF) 2028450. *'A centralised platform for functional high-risk multiple myeloma – The ZEPFHR MM Trial (AMaRC 22-03)'.* **$3,417,815**
36. 2024-2027. Medical Research Futures Fund (MRFF) 2035395. *'Harnessing the circulating genome to improve diagnosis and outcomes for patients with multiple myeloma: the Genomic Liquid biopsy Analysis for Myeloma (GLAM) study'.* **$1,701,126**
37. 2024-2025. MPCCC Precision Treatment Accelerator. 'Establishing blood-based liquid biopsies for early detection of high-risk multiple myeloma'. **$143,729.**
38. 2024 – 2025. Barrie Dalgleish Centre Grant. 'Understanding the molecular drivers of extramedullary multiple myeloma using liquid biopsies and PET-CT imaging'. **$499,268**

Pre-Clinical Collaborations

1. 2000. Novartis Pharmaceuticals Australia Pty Ltd. 'Evaluation of the anti-tumour potential of zoledronic acid in multiple myeloma'. **$10,000.**

2. 2001-2002. Novartis Pharma, Switzerland. 'Evaluation of the anti-tumour potential of zoledronic acid in multiple myeloma'. **$65,000**.
3. 2004-2005. Pharmion Pty Ltd. 'In vitro evaluation of azacitidine in multiple myeloma'. **$35,000.**
4. 2005-2006. Novartis Pharmaceuticals Australia Pty Ltd. 'Pre-clinical evaluation of the Focal Adhesion Kinase (FAK) inhibitor TAE226 as a potential therapeutic agent for the treatment of multiple myeloma'. **$34,000.**
5. 2006-2008. Novartis Pharmaceuticals Australia Pty Ltd. 'Pre-clinical evaluation of novel therapies in multiple myeloma'. **$414,000**
6. 2007. Cytopia Research Pty Ltd. 'Preclinical evaluation of CYT997 with in vitro models of multiple myeloma'. **$35,000.**
7. 2007-20013. Immune Systems Therapeutics. 'Pre-clinical evaluation of a chimaeric anti-kappa monoclonal antibody (MDX1097) for multiple myeloma'. **$140,000** per year.
8. 2008. Cytopia Research Pty Ltd. 'Preclinical evaluation of kinase inhibitors with in vitro models of multiple myeloma'. **$65,000.**
9. 2008. Novartis Pharmaceuticals Australia Pty Ltd. 'Pre-clinical evaluation of a novel heat shock protein inhibitor (HSP990) for multiple myeloma'. **$80,000.**
10. 2010. Janssen-Cilag. 'Tissue array as a predictor of MM response to novel therapeutics'. **$95,850.**
11. 2010-11. Merck Sharp & Dohme. Pre-clinical studies of Vorinostat in multiple myeloma'. **$80,831**
12. 2010-11. Celgene Corporation. 'Mechanisms of action of novel immunomodulatory agents in multiple myeloma'. **$60,000.**
13. 2011. Novartis Oncology. 'Pre-clinical evaluation of FGFR3 inhibition in multiple myeloma'. **$50,000**
14. 2016. Servier/Novartis Oncology. 'MCL-1 inhibition of primary myeloma tumours'. **$150,000**
15. 2016. BetaCat. 'In vivo drug combination studies utilizing BVC2059'. **$130,000**
16. 2019-2020. PharmaMar. 'Mechanism of resistance to Aplidin'. **$148,000**
17. 2019-2022. BMS/Celgene. 'Pre-clinical evaluation of CELMoDs'. **$440,000**
18. 2019-2022. Haemalogix. 'Evaluation of the role of KMA in myeloma biology and strategies for enhanced clinical targeting'. **$430,000**
19. 2020-2022. Abbvie. 't(11;14) and BCL2/CCND1 expression in multiple myeloma patients: Concordance across sample types'. **US$217,218 (AUD$323,630).**
20. 2020-2022. Antegene Australia. 'An exploratory study of cfDNA clonal response and dynamics in multiple myeloma and acute myeloid leukaemia patients undergoing RAS-MAPK targeted treatment with ATG-017'. **$191,000**
21. 2022-2022. Antegene Australia. 'Evaluating the therapeutic potential of adenosine signalling blockade by ATG-047 in pre-clinical models of multiple myeloma'. **$166,834**

<u>Investigator Initiated Trials</u>

1. 1997-1999. Pharmacia & Upjohn Pty Ltd / Amgen Australia Pty Ltd. 'A Phase II trial of a novel chemotherapeutic regimen (CID) and early peripheral blood stem cell transplantation (PBSCT) for multiple myeloma'. **$49,800**.
2. 1999-2001. Schering-Plough Pty Ltd / Amgen Australia Pty Ltd. 'A multicentre Phase IV randomised trial of amifostine cytoprotection in patients undergoing autologous peripheral blood stem cell transplantation (PBSCT) for multiple myeloma using single agent high-dose melphalan followed by interferon–alpha maintenance therapy'. **$120,000**.
3. 1999. Amgen Australia Pty Ltd. 'A pilot study of melphalan 220 mg/m and amifostine cytoprotection as conditioning for autologous stem cell transplantation in patients with multiple myeloma'. **$3,000.**
4. 2001-2002. Asta Medica pty Ltd. / Amgen Australia Pty Ltd. 'A pilot study of outpatient vinorelbine and Gemcitabine with filgrastim support for patients with relapsed or refractory lymphoma'. **$60,000.**

5. 2003-2004. Novartis Pharmaceuticals Australia Pty Ltd. 'A Phase II study evaluating the clinical and biological activity of fluvastatin-zoledronic acid induced mevalonate pathway inhibition in patients with advanced multiple myeloma'. **$20,000.**
6. 2002-2003. Progen Industries Limited. 'A Phase II study of PI-88 in refractory or relapsed multiple myeloma'. **$75, 477.**
7. 2002-2004. Baxter Oncology / Amgen Australia Pty Ltd. 'A multicentre Phase II study of risk-adjusted outpatient-based salvage therapy for patients with relapsed and refractory lymphoma'. **$116,250.**
8. 2002-2004. Novartis Pharma, USA. 'Pharmacokinetics and renal safety of zoledronic acid given alone and in combination with thalidomide'. **$240,000**.
9. 2002-2004. Novartis Pharmaceuticals Australia Pty Ltd / Amgen Australia Pty Ltd / Pharmion Pty Ltd. 'A multicentre randomised Phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid for post-ASCT maintenance therapy in patients with multiple myeloma (ALLG MM6)'. **$1,100,000**.
10. 2004-2006. Amgen Australia Pty Ltd. 'Kinetics of engraftment and supportive care requirements post-high-dose melphalan conditioned stem cell transplantation using pegylated granulocyte colony stimulating factor'. **$224,000.**
11. 2004-2007. Pharmion Pty Ltd. 'A multicentre randomised Phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid for post-ASCT maintenance therapy in patients with multiple myeloma (ALLG MM6)'. **$120,000**.
12. 2006. Novartis Pharmaceuticals Australia Pty Ltd. 'Pilot Study of investigational biomarker analyses for early Phase trials in multiple myeloma'. **$21,000.**
13. 2006. Novartis Pharmaceuticals Australia Pty Ltd. 'Osteonecrosis of the jaw (ONJ) MM6 Survey'. **$35,000.**
14. 2006-2007. Amgen Australia Pty Ltd. 'A 3-Stage Phase I/II dose-escalation study of high-dose melphalan with palifermin for patients with multiple myeloma'. **$121,600.**
15. 2006-2008. Pharmion Pty Ltd. 'Phase II trial of azacitidine for relapsed multiple myeloma and parallel translational studies'. **$298,000.**
16. 2009–2012. Novartis Oncology/Novartis Pharmaceuticals Australia Pty Ltd. 'A Phase Ib Clinical Evaluation Of The Safety And Efficacy Of Combining Panobinostat With 5-Azacytidine In Untreated Elderly Patients With High-Risk MDS or AML'. **$770,000.**
17. 2010-2012. Celgene Pty Ltd. 'Exploratory evaluation of minimal residual disease (MRD) detection strategies and kinetics in multiple myeloma (MM) patients treated with Revlimid and alternate day prednisolone maintenance therapy following high-dose melphalan (HDM) conditioned autologous stem cell transplantation (ASCT)'. **$318,000.**
18. 2011-2013. Janssen-Cilag. 'BRIMM: A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with MM'. **$225,000.**
19. 2012-2014. Celgene Pty Ltd. 'A Randomised Phase II Study of Single Agent Pomalidomide Maintenance Versus Combination Pomalidomide and Low Dose Dexamethasone Following Induction with the Combination of Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed and Refractory Myeloma Previously Treated with Lenalidomide'. **$480,000.**
20. 2012-2014. Novartis Oncology. A 2-stage Phase II study of panobinostat in myeloma patients with <VGPR following high-dose chemotherapy conditioned ASCT. **$553,047.**
21. 2012-2015. Janssen Pty Ltd. An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Versus Thalidomide and Prednisolone Alone in Previously Untreated Subjects with Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant (VCAT) – ***Correlative laboratory studies*** **$300,000.**
22. 2014-2017. Celgene Pty Ltd. A Phase Ib trial of continuous oral azacytidine in combination with

lenalidomide and dexamethasone (Rd) for myeloma patients with relapsed and/or refractory disease who have failed a prior lenalidomide-containing regimen. **$210,000**

23. 2015-2017. Celgene Pty Ltd. A 2-stage Phase II study of combination pomalidomide and low dose dexamethasone therapy in patients with relapsed myeloma previously treated with lenalidomide maintenance post Autologous Stem Cell Transplant (LEOPARD follow-on study). **$251,940**

24. 2015-2017. Celgene Pty Ltd. Lenalidomide consolidation post allogeneic stem cell transplant for patients with high risk multiple myeloma failing to achieve stringent CR. **$229,500**

Current Investigator Initiated Trials

25. 2016-2020. Amgen/Onyx Pharmaceuticals. A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (KTd) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy – ALLG MM17. **$573,000**

26. 2016-2018. Takeda Oncology. A prospective multi-centre single arm phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy (IISR-2015-101017). **$494,853**

27. 2016-2020. Takeda Oncology. A phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamtheasone-MLN9708 consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy (IISR-2013-M100173). **$2,444,796**

28. 2016-2021. BMS. A multicenter phase 3 trial comparing elotuzumab-cyclophosphamide-thalidomide-dexamethasone (E-CTD) with cyclophosphamide-thalidomide-dexamethasone (CTD) for the treatment of relapsed and/or refractory multiple myeloma (RRMM). **$2,400,000**

29. 2018-2020. Celgene Pty Ltd/Janssen Pty Ltd. A multicentre single arm study of DRd for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy. **$655,000**

30. 2018-2020. Abbvie Pty Ltd. An exploratory study of venetoclax in combination with bortezomib-cyclophosphamide-dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies. **$460,091**

31. 2020-2024. BMS. 'Frailty-stratified, randomized controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - FRAIL-M study' – Correlative studies. **$646,000.**

32. 2021-2022. Janssen Pty Ltd. 'A PRO-based prospective evaluation of barriers to treatment and treatment satisfaction with daratumumab-velcade-dexamethasone'. **$178,000**

33. 2023-2027. BMS/Sanofi. 'AMaRC 20-01. An immune-therapeutic salvage strategy for functional high-risk multiple myeloma incorporating iberdomide, isatuximab and dexamethasone (IBIS)'. **$945,843**

34. 2023-2028. Antegene. 'AMaRC 21-04. Risk directed front-line therapy for multiple myeloma incorporating Selinexor: The RIDDLE-M-X trial'. **$1,995,000**

Other funding

1. 1996. Research seeding grant – Hunter Area Pathology Service. **$90,000.**

2. 2000-2002. Amgen Australia Pty Ltd. Unrestricted research grant. **$90,000.**

3. 2004. Amgen Australia Pty Ltd. Clinical projects infrastructure grant. **$16,000.**

4. 2008. Novartis Pharmaceuticals Australia Pty Ltd. Research & Education Grant. **$50,000.**

5. 2010-2012. Merrin Foundation Myeloma Fellowship. **$270,000**

6. 2010-2012. Celgene Pty Ltd. Unrestricted Trial Infrastructure Support Grant. **$300,000**

7. 2011-2013. Kefford Leukaemia Research Fellowship. **$300,000**

8. 2012-2016. Celgene/Novartis/BMS/Amgen/Janssen-Cilag/Takeda. Establishment of the 'Myeloma & Related Diseases Registry and The Myeloma 1000 Biobank'. **$775,000**
9. 2013-2015. Merrin Foundation Myeloma Fellowship. **$300,000**
10. 2016-2018. Merrin Foundation Myeloma Fellowship. **$300,000**
11. 2016-2018. Henry Jolson Translational Research Fellowship. **$365,000**
12. 2016-2017. Janssen-Cilag. Clinical Myeloma Fellowship. **$180,000**
13. 2017-2021. Janssen-Cilag. APAC expansion of the MRDR. **$1,660,000.**
14. 2018-2020. Merrin Foundation Myeloma Fellowship**. $500,000**
15. 2018-2019. GSK Australia Pty Ltd. Myeloma and Related Diseases Registry. **$50,000**
16. 2018-2020. Janssen-Cilag. APAC Myeloma and Related Diseases Registry. **$1,663,668**
17. 2018-2020. Celgene Pty Ltd. Myeloma and Related Diseases Registry. **$450,000**
18. 2019-2020. Sanofi. Myeloma and Related Diseases Registry. **$20,000**
19. 2019-2020. Janssen-Cilag. Myeloma and Related Diseases Registry. **$55,169**
20. 2019-2023. BMS. Myeloma and Related Diseases Registry. **$600,000**
21. 2020-2022. Abbvie. Myeloma and Related Diseases Registry. **$150,000**
22. 2021-2025. Janssen-Cilag. APAC Myeloma and Related Diseases Registry. **$5,290,000**
23. 2022-2024. Tegner Myeloma Fellowship. **$150,000**
24. 2023-2025. Banbery Myeloma Fellowship**. $100,000**
25. 2023-2024. European Myeloma Network Biobank. **$336, 000**

Patents

1. Combination therapy comprising a bisphosphonate and a HMG-CoA reductase inhibitor. US Patent APP. 10/526,282. 8/9/2003
2. Combination therapy comprising a bisphosphonate and a HMG-CoA reductase inhibitor. EP Patent 1,539,186. 15/6/2005
3. Combination therapy comprising a bisphosphonate and a HMG-CoA reductase inhibitor. US Patent APP. 112/431,347. 28/4/2009
4. Multiple myeloma treatment (CYT387). International Patent WO/2012/149602. 8/11/2012

Publications[1]

Refereed Journal Articles

1. Macdonald D, Sheerin SM, Cross NCP, **Spencer A**, Goldman JM. An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case. *British Journal of Haematology* 1994; 86: 879-880.
2. Garicochea B, van Rhee F, **Spencer A**, Chase A, Lin F, Cross NCP, Goldman JM. Aplasia after donor lymphocyte infusions (DLI) for CML in relapse after sex-mismatched BMT: Recovery of donor-type haematopoiesis predicted by non-isotopic in situ hybridisation (ISH). *British Journal of Haematology* 1994; 88: 400-402.
3. van Rhee F, Feng L, Cullis JO, **Spencer A**, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of Chronic Myeloid Leukaemia after allogeneic bone marrow transplantation: The case for giving donor leukocyte transfusions before the onset of haematological relapse. *Blood* 1994; 83: 3377-3383.
4. Gill DS, **Spencer A**, Cobcroft RG. High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. *British Journal of Haematology* 1994; 88: 204-206.

[1] Citations 303831; h-index 77; i10-index 225

5. **Spencer A**, Brookes PA, Kaminski E, Hows JM, Szydlo RM, van Rhee F, Goldman JM, Batchelor JR. Cytotoxic T-lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors: value in donor selection. *Transplantation* 1995; 59: 1302-1308.
6. **Spencer A**, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia with volunteer unrelated donors using 'ex-vivo' or 'in-vivo' T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. *Blood* 1995; 86: 3590-3597.
7. **Spencer A**, Vulliamy T, Chase A, Goldman JM. Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia. *Leukemia* 1995; 9: 2138-2139.
8. Kirkland MA, **Spencer A,** Davidson RJ, McDonald C, Goldman JM. Quantitation of mafosfamide-resistant pre-CFU in allogeneic bone marrow transplantation: relationship with rate of engraftment and evidence for long-lasting reduction in stem cell numbers. *Blood* 1996; 87: 3963-3969.
9. Al-Jehani F, Hochhaus A, **Spencer A**, Goldman JM, Melo JV. Expression of the LH2 gene in chronic myeloid leukaemia. *Leukemia* 1996; 10: 1122-1126.
10. Horgan SE, Beaconsfield M, Fraser SG, Ferrante PF, **Spencer A**. Cystoid macular oedema in chronic myeloid leukaemia: treatment with acetazolamide and response to bone marrow transplantation. *Eye* 1996; 10: 394-396.
11. **Spencer A**, Yan XH, Chase A, Goldman JM, Melo JV. BCR-ABL positive lymphoblastoid cells display limited proliferative capacity under in-vitro culture conditions. *British Journal of Haematology* 1996; 94: 654-658.
12. Savage DG, Taylor P, Blackwell J, Chen F, Szydlo RM, Rule SAJ, **Spencer A,** Apperley JF, Goldman JM. Paranasal Sinusitis following Allogeneic Bone Marrow Transplantation. *Bone Marrow Transplantation* 1997; 19: 55-59.
13. **Spencer A**, Vulliamy T, Goldman JM, Melo JV. Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukaemia. *Leukemia* 1997; 195-201.
14. Grand FH, Marly SB, Chase A, Tetley I, Healy L, **Spencer A,** Reiter A, Goldman JM, Gordon MY. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukaemia patients. *Leukemia* 1997; 11: 1486-1492.
15. **Spencer A**, Granter N, Fagan K, Zaunders G, Deveridge SF. Collection and analysis of peripheral blood mononuclear cells during haemopoietic recovery following PBSCT for CML: autografting as an *in vivo* purging manoeuvre? *Bone Marrow Transplantation* 1998; 21: 101-103.
16. **Spencer A,** Szydlo R, Grand FH, Goldman JM, Melo JV. Abnormal patterns of IgH gene DNA fingerprinting during chronic phase CML. *Leukemia and Lymphoma* 1999; 32: 299-307.
17. **Spencer A**, Firkin F. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: Initial Australian experience. *Australia and New Zealand Journal of Medicine* 1999; 29: 385-386.
18. **Spencer A,** Granter N. Leukemia-patient derived lymphoblastoid cell lines exhibit increased induction of leukaemia-associated transcripts following high-dose irradiation. *Experimental Hematology* 1999; 27: 1397-1401.
19. Millar EKA, Waldron S, **Spencer A,** Braye S. CD10 positive thyroid marginal zone non-Hodgkin's lymphoma. *Journal of Clinical Pathology* 1999; 52: 849-850.
20. Lincz L, Crooks R, Way S, Granter N, **Spencer A**. Tumour kinetics in multiple myeloma before, during and after treatment. *Leukemia and Lymphoma* 2001; 40: 373-384.
21. Kannan K, Szer J, **Spencer A**, Schwarer AP, Grigg A. Chemotherapy and donor leukocyte infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation. *Internal Medicine Journal* 2001; 31: 15-22.
22. Tait BD, Maddison R, McCluskey J, Deayton S, Lester S, Bardy P, Szer J, Grigg A, **Spencer A,** Schwarer A, Holdsworth R. Clinical relevance of the minor histocompatibility antigen HA-1 in

allogeneic bone marrow transplantation between HLA siblings. *Transplantation Proceedings* 2001; 33: 1760-1761.

23. Kerridge I, **Spencer A,** Azzi A, Seldon M. Response to erythropoietin in chronic myelomonocytic leukaemia. *Internal Medicine Journal* 2001; 31: 371-372.

24. Lincz L, Yeh SL, **Spencer A.** TRAIL induced eradication of primary tumour cells from multiple myeloma patients bone marrows is not related to TRAIL receptor expression or prior chemotherapy. *Leukemia* 2001; 15: 1650-1657.

25. **Spencer A**, Jackson J, Baulch-Brown C. Enumeration of bone marrow 'homing'; haemopoietic stem cells from G-CSF mobilised normal donors and influence on engraftment following allogeneic transplantation. *Bone Marrow Transplantation* 2001; 28; 1019-1022.

26. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, **Spencer A.** Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. *British Journal of Haematology* 2002; 118: 477-481.

27. **Spencer A,** Yeh SL, Koutrouvelis K, Baulch-Brown C. TRAIL-induced apoptosis of authentic myeloma cells dose not correlate with the pro-caspase8/cFLIP ratio. *Blood* 2002; 100: 3049-3050.

28. Lincz L, Scorgie F, Kerridge I, Potts R, **Spencer A,** Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. *British Journal of Haematology* 2003; 120: 1051-1054.

29. Howden B, Michaelidis A, Spelman D, **Spencer A,** Schwarer A, Wesselingh S, Kotsimbos T. Cytomegalovirus (CMV) viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis. *Bone Marrow Transplantation* 2003; 32: 795-800.

30. **Spencer A,** Seldon M, Deveridge S, Cobcroft R, Cull G, Marlton P, Enno A, Gill D. Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. *Haematologica - The Hematology Journal* 2004; 5: 216-221.

31. Lincz L, Kerridge I, Scorgie F, Bailey M, Enno A, **Spencer A.** Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. *Haematologica - The Hematology Journal* 2004; 89: 121-122.

32. Herbert KE, **Spencer A,** Grigg A, Ryan G, McCormack C, Prince H. Graft-versus-lymphoma effect in refractory Cutaneous T cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. *Bone Marrow Transplantation* 2004; 34: 521-525.

33. Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, **Spencer A,** Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. *Annals of Oncology* 2004; 15: 1810-1815.

34. **Spencer A**, Horvath N, Gibson J, Prince M, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K. A prospective randomised trial of Amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. *Bone Marrow Transplantation* 2005; 35: 971-977.

35. Dawson M, **Spencer A**. Successful use of haploidentical stem cell transplantation with KIR mismatch as initial therapy for poor risk Myelodysplastic Syndrome. *Journal of Clinical Oncology* 2005; 23: 4473-4474.

36. Dawson M, Schwarer A, Miurhead J, Bollard G, Bailey M, **Spencer A**. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who had failed a previous attempt using a granulocyte colony stimulating factor-based regimen. *Bone Marrow Transplantation* 2005; 36: 389-396.

37. Nandurkar D, Kalff V, Turlakow A, **Spencer A,** Kelly MJ. Focal MIBI Uptake is a Better Indicator Of Active Myeloma Than Diffuse Uptake. *European Journal of Hematology* 2006; 76: 141-146.

38. Shortt J, Hutton A, Farragher M, **Spencer A**. Central nervous system graft-versus-host-disease post-allogeneic stem cell transplant. *British Journal of Haematology* 2006; 132: 245-246.

39. Dawson M, Polizzotto M, Gordon A, Roberts S, **Spencer A.** Extramedullary relapse of multiple myeloma presenting as hematemesis and melena following stem-cell transplantation and targeted biological therapy. *Nature Clinical Practice - Oncology* 2006; 3:223-226.

40. Seshadri T, Gook D, Lade S, **Spencer A**, Grigg A, Tiedemann K, McKendrick J, Mitchell P, Stern C, Seymour JF. Lack of evidence of disease contamination in cryopreserved ovarian tissue harvested from patients with Hodgkin Lymphoma and analysis of factors predictive of oocyte yield. *British Journal of Cancer* 2006; 94: 1007-1010.

41. Shortt J, **Spencer A.** Adjuvant Rituximab causes prolonged hypo-gammaglobulinaemia following autologous stem cell transplantation for non-Hodgkin's lymphoma. *Bone marrow Transplantation* 2006; 38: 433-436.

42. Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, **Spencer A**, Herrmann R, Arthur C, Durrant S, Van Kerkhoven M, Macmillan J, Mrongovius R. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. *Leukemia & Lymphoma* 2006; 47: 2344-2350.

43. Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, **Spencer A.** Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. *Leukemia Research* 2007; 31: 341-352.

44. Baker M, Allen P, Shortt J, Lewin SR, **Spencer A.** Immune recovery uveitis in HIV-infected and HIV-negative immunosuppressed individuals in Australia: Clinical Case notes. *Clinical and Experimental Opthalmology* 2007: 189-190.

45. Sharkey J, Khong T, **Spencer A.** PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. *Blood* 2007; 109: 1712-1719.

46. Dawson M, Patil S, **Spencer A**. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. *Haematologica – The Hematology Journal* 2007; 92: 143-144.

47. **Spencer A**, Reed K, Arthur C. A pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim (VGF). *Internal Medicine Journal* 2007; 37: 760-766.

48. Slavin MA, Grigg AP, Schwarer AP, Szer J, **Spencer A,** Sainani A, Thursky KA, Roberts A. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2007; 40: 157-163.

49. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, **Spencer A**, San Miguel J, Robak T, Dmoszynska A, Horvath N, Ivan Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. The combination of pegylated liposomal Doxorubicin and Bortezomib significantly improves time to progression of patients with relapsed/refractory Multiple Myeloma compared with Bortezomib alone: Results from a randomized Phase III study. *Journal of Clinical Oncology* 2007; 25: 3892-3901.

50. Dimopoulos M, **Spencer A**, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellman A, Facon T, Foa R, Lazzarino M, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD. Oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. *New England Journal of Medicine* 2007; 357: 2123-2132.

51. Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van't Veer MB, Milpied N, Carton G, Pezzuto A, **Spencer A**, Reyes F, Dreyling M. A Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. *Annals of Oncology* 2007; 19: 247-253.

52. Sonneveld P, Hajek R, Nagler A, **Spencer A**, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ. Combined Pegylated Liposomal Doxorubicin and Bortezomib Is Highly Effective in Patients with Relapsed or Refractory Multiple Myeloma Who Have Received Prior Thalidomide/Lenalidomide Therapy. *Cancer* 2008; 112: 1529-1537.

53. Kalff A, Shortt J, Farr J, McLennan R, Lui A, Scott J, **Spencer A.** Laboratory tumour lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia. *Haematologica* 2008; 93: e16-17.

54. **Spencer A,** Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, Neeman T, Copeman M, Schran H, Lynch K. Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. *BMC Clinical Pharmacology* 2008; 8: 2.

55. Khong T, Sharkey J, **Spencer A.** The effect of azacitidine on IL-6 signalling and nuclear factor-kB activation and it's *in vitro* and *in vivo* activity against multiple myeloma. *Haematologica* 2008; 93: 860-869.

56. Sant-Rayn P, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario JD, Lowenthal R, Taylor K, Reed K, **Spencer A.** A multi-centre Phase II study of risk-adapted salvage therapy incorporating vinorelbine and gemcitabine in an ambulatory care setting for relapsed and refractory lymphoma. *Cancer* 2008; 113 (11); 3192-3198.

57. Blade J, Sonneveld P, San Miguel J, Sutherland H, Hajek R, Nagler A, **Spencer A**, Robak T, Cibeira M, Zhuang S, Harousseau JL, Orlowski R. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. *Clinical Lymphoma & Myeloma* 2008; 8(6): 352-355.

58. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, **Spencer A**, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. *Blood* 2008; 112(12): 4445-4451.

59. Dawson M, Opat S, Taouk Y, Donovan M, Monaghan K, Horvath N, Roberts A, Prince HM, Hertzberg M, McLean C, **Spencer A.** Clinical and immunohistochemical features associated with response to bortezomib in patients with multiple myeloma. *Clinical Cancer Research* 2009; 15: 714-722.

60. **Spencer A,** Prince HM, Roberts AW. Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplant (ASCT) procedure. *Journal of Clinical Oncology* 2009; 27: 1788-1793.

61. Prince HM, Honemann D, **Spencer A,** Rizzieri DA, Stadtmauer EA, Roberts AR, Bahlis N, Bell W, De Marini DJ, Suttle AB, Baker KL, Pandite LN. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A Phase II study of pazopanib (GW786034). *Blood* 2009; 113: 4819-4810.

62. Dimopoulos MA, Chen C, **Spencer A**, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. *Leukemia* 2009; 23: 2147-2152.

63. Polizzotto MN, Skinner M, Cole-Sinclair MF, Opat S, **Spencer A,** Avery S. Allo-SCT for hematological malignancies in the setting of HIV. *Bone Marrow Transplantation* 2009; 45: 584-586.

64. Patil S, **Spencer A,** Schwarer A, Avery S, Ritchie D, Opat S, Wei A, McClean C. Disease status at autologous transplantation (ASCT) and the cell of origin phenotype are important predictors of outcome in patients with neurologic (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) undergoing ASCT. *Leukemia & Lymphoma* 2009; 50: 1964-1968.

65. Dickinson M, Ritchie D, DeAngeloa D, **Spencer A,** Ottman O, Fischer T, Bhalla K, Liu A, Parker K, Scott J, Bishton M, Prince M. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. *British Journal of Haematology* 2009; 147: 97-101.

66. Brown R, **Spencer A,** Ho J, Kennedy N, Kabani K, Yang S, Sze D, Akiliu E, Gibson J, Joshua D. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. *Leukemia & Lymphoma* 2009; 50: 1860-1864.

67. Vij R, Horvath N, **Spencer A,** Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. An open label phase 2 trial of denosumab in the treatment of relapsed or plateau phase multiple myeloma. *American Journal of Hematology* 2009; 84: 650-656.

68. Patil S, **Spencer A,** Schwarer A, Lewis I, Hertzberg M, Avery S, Wei A, Noutsos T, Paul E, Taouk Y, Muirhead J. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. *Bone Marrow Transplant* 2010; 45 (7):1154-60.

69. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, **Spencer A**, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. *Haematologica – The Hematology Journal* 2010; 95: 1738-1744.

70. Monaghan K. Khong T, Smith G, **Spencer A.** CYT997 causes apoptosis in human myeloma cells. *Investigational New Drugs* 2011; 29(2): 232-238.

71. Blade J, Sonneveld P, San Miguel J, Sutherland HJ, Hajek R, Nagler A, **Spencer A,** Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski R. Efficacy and safety of pegylated doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome. *Clinical Lymphoma and Myeloma* 2011; 11(1): 44-49.

72. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, **Spencer A**, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. *Journal of Clinical Oncology* 2011; 29(9): 1125-32.

73. Monaghan K, Khong T, **Spencer A.** The novel JAK2 inhibitor CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. *Leukemia* 2011; 25: 1891-1899.

74. Grigoriadis G, Chang CC, Walker P, Patil S, Avery S, Morrissey O, **Spencer A.** Failure of haematopoietic recovery overcome by SCT despite invasive mucormycosis infection. *Bone Marrow Transplantation* 2011; 47: 5910592.

75. Khong T & **Spencer A.** Targeting HSP90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. *Molecular Cancer Therapeutics* 2011; 10(10); 1909-17.

76. Millward M, Price T, Townsend A, Sweeney C, **Spencer A**, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat. *Investigational New Drugs* 2012; 30 (6): 2303-2317.

77. Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim C, Browne P, Einsele H, Waage A, Turesson I, **Spencer A**, Hajek R, Ludwig H, Hemminki K, Houlston R. MAGIC (MyelomA Genetics International Consortium). *Leukemia & Lymphoma* 2012; 53 (5):796-800.

78. Ho PJ, Brown RD, **Spencer A,** Jeffels M, Daniher D, Gibson J, Joshua DE. Thalidomide consolidation improves progression-free survival in myeloma with normal but not upregulated expression of FGFR3: Analysis from the ALLG MM6 clinical trial. *Leukemia & Lymphoma* 2012; 53 (9): 1728-1734.

79. Coutsouvelis J, Wiseman M, Hui L, Poole S, Dooley M, Patil S, Avery S, Wei A, **Spencer A**. Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome. *British Journal of Clinical Pharmacology* 2012 (DOI: 10.1111/j.1365-2125.2012.04355).

80. Bensinger W, Maziarz RT, Jagannath S, **Spencer A**, Durrant S, Becker PS**,** Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer EA. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist

monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. *British Journal of Haematology* 2012; 159 (1): 58-66.

81. Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, **Spencer A,** Wei A. High-dose cytarabine (24g/m) in combination with idarubicin (HiDAC-3) results in high furst cycle response with limited gastro-intestinal toxicity in adult myeloid leukaemia. *Internal Medicine Journal* 2013; 43 (3): 294-297.

82. Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, **Spencer A,** Schwarer A, Wei A. FLAG-amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. *Leukemia & Lymphoma* 2013; 54 (2): 336-341.

83. DeAngelo DJ, **Spencer A,** Bhalia KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, 2-arm. Open-label, dose-escalation study of oral panobinostat administered via 2 dosing schedules in patients with advanced hematologic malignancies. *Leukemia* 2013; 27(8): 1628-1636

84. Mithraprabhu S, Khong T, Jones SS, **Spencer A.** Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of Class I HDAC. *British Journal of Haematology* 2013; 162 (4): 559-562.

85. Lee D, Kalff A, Low M, Gangatharan S, Ho P, Bajel A, Ritchie D, Grigg A, **Spencer A**. Central nervous system multiple myeloma – potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. *British Journal of Haematology* 2013; 162 (3): 371-375.

86. Bishton M, **Spencer A**, Dickinson M, Ritchie D. A single arm, Phase II study of the anti-Blys monoclonal antibody Belimumumab in symptomatic Waldenstrom Macroglobulinaemia. *Clinical Lymphoma, myeloma & Leukemia* 2013; 13 (5): 575-578.

87. Dimopoulos M, Jagannath S, Yoon Sung-Soo, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, **Spencer A**, Palumbo A, Reece D, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KA. Vantage 88: An international, multicenter, randomized, double-blind study of vorinostat (MK-0683) or placebo in combination with bortezomib in patients with multiple myeloma. *Lancet Oncology* 2013; 14 (11): 1129-1140.

88. Govindaraj C, Tan P, Walker P, Wei A, **Spencer A**, Plebanski M. Reducing TNF Receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor panobinostat for clinical benefit in acute myeloid leukaemia patients. *Clinical Cancer Research* 2014; 20(3): 724-735.

89. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, **Spencer A**. Dual Epigenetic Targeting with Panobinostat and Azacitidine in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. *Blood Cancer Journal* 2014; **4**, e170; doi:10.1038/bcj.2013.68

90. Campbell P, Walker P, Avery S, Patil S, Curtis D, Schwarer A, Wei A, Kalff A, Muirhead J, **Spencer A.** Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma. *Blood Cancer Journal* 2014; **4**, e213; doi:10.1038/bcj.2014.33

91. Liu HB, Urbanavicius D, Tan P, **Spencer A**, Dear AE. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies. *International Journal of Oncology* 2014; 45(4): 1742-1748.

92. Macesic N, Morrissey O, Cheng A, **Spencer A**, Peleg A. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: Increasing resistance over a 9-year period. *Transplant Infectious Disease* 2014; 16(6): 887-896.

93. **Spencer A**, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics and clinical activity in multiple myeloma. *Blood* 2014; 124: 2190

94. Kalff A, Kennedy N, Smiley A, Prince HM, Roberts AW, Bradstock K, De Abreu Lourenco, Frampton C, **Spencer A**. Thalidomide and prednisolone versus prednisolone alone as consolidation therapy

after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. *Lancet Haematology* 2014; 1(3): e112-119.

95. Doan TN, Kong D, Patela K, Walker P, **Spencer A**, Kirkpatrick CMJ. Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia. *International Journal of antimicrobial agents* 2014 Nov; 44(5): 450-457.

96. Mithraprabhu S, Khong T, **Spencer A.** Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. *Cell Death and Disease* 2014; **5**, e1134

97. Bilmon I, Nivison-Smith I, Hertzberg M, Ritchie D, Greenwood M, **Spencer A**, Kennedy G, Bryant A, Moore J. Outcomes following second allogeneic haematopoietic transplants using Fludarabine-Melphalan conditioning. *Bone Marrow Transplantation* 2014; 49(6): 852

98. San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, **Spencer A**, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Phase 2 randomised study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood* 2014; 123(26): 4136-4142.

99. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, **Spencer A**, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: meta-analysis of individual patient data. *Lancet Oncology* 2014; 15(3): 333-342.

100. Mithraprabhu S, Kalff A, Chow A, Khong T, **Spencer A**. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. *Epigenetics* 2014; 9(11): 1511-1520. **IF 4.17 CIT 66**

101. Kalff A, Khong T, Wall M, Gorniak M, Mithraprabhu S, Campbell LJ, **Spencer A**. A rare case of *IGH/MYC* and *IGH/BCL2* double hit primary plasma cell leukemia. *Hematologica* 2015 Feb; 100(2):e60-62.

102. Fedele PL, Avery S, Patil S, **Spencer A**, Haas M, Wei A. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. *Internal Medicine Journal* 2014; 44(8): 757-763.

103. Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D, George B, Hertzberg M, Patil S, **Spencer A**, Fay K, Cannell P, Berkahn, Doocey R, Spearing R, Moore J. Fludarabine Melphalan reduced-intensity conditioning allotransplantation provides similar disease control in lymphoid and myeloid malignancies: Analysis of 344 patients. *Bone Marrow Transplantation* 2014; 49(1): 17-23.

104. Asvadi P, Cuddihy A, Dunn R, Jiang V, Wong M, Khong T, **Spencer A**. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. *British Journal of Haematology* 2015 May; 169(3).

105. Wei A, Tan P, Perruzza S, Govindaraj C, Fleming S, McManus J, Avery S, Patil S, Stevenson W, Plebanski M, **Spencer A**. Maintenance lenalidomide in combination with 5-azacitidine for patients with acute myeloid leukemia at high risk of relapse. *British Journal of Haematology* 2015 Apr; 169(2):199-210.

106. Scheid C, Reece D, Beksac M, **Spencer A**, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart K. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. *European Journal of Haematology* 2015; 95(4); 316-324.

107. Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M, Van De Velde H, Schwarer A, Baker B, **Spencer A**, Catalano J, Campbell P, Augustson B, Romeril K, Prince HM. The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but

ongoing maintenance therapy has minimal benefit. *American Journal of Hematology* 2015; 90(5): E86-91.

108. Seggewiss-Bernhardt R, Bargou R, Goh YT, Stewart K, **Spencer A,** Alegre A, Blade J, Ottman O, Fernandez-ibarra C, Lu H, Pain S, Akimov M, Iyer S. A Phase 1/1B Trial of the HSP90 Inhibitor NVP-AUY922 Monotherapy or in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma. *Cancer* 2015 March 24. doi: 10.1002/cncr.29339

109. Diel J, Body JJ, Stopeck AT, Vadhan-Raj S, **Spencer A**, Steger G, von Moos R, Goldwasser F, Feng A, Braun A. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. *European Journal of Cancer* 2015: 51(11): 1467-1475.

110. Harrison SJ, Quach H, **Spencer A**, Prince HM. Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". *Haematologica* 2015 Sep:100(9): e379. 10.3324/ haematol.2015. 128470.

111. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, **Spencer A**, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. *Haematologica*. 2015 Oct;100(10):1327-33.

112. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, **Spencer A,** Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart E, Anderson KC, Richardson P. Elotuzumab therapy for relapsed or refractory multiple myeloma. *New England Journal of Medicine* 2015; 373(7): 621-631.

113. Pham T, Patil S, Fleming S, Avery S, Walker P, Wei A, Curtis D, Stuart G, Klarica D, O'Brien M, Morris K, Das T, Bollard G, Muirhead J, Coutsouvelis J, **Spencer A**. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. *Transfusion*. 2015 Jul14. doi: 10.1111/trf.13233. [Epub ahead of print]

114. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, **Spencer A**, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomized, multicenter, phase 3 trial. *Lancet Oncology* 2015; 16(16): 1617-1629.

115. Raje N, Vadhan-Raj s, Willenbacher W, Terpos E, Hungria V, **Spencer A**, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trail. *Blood Cancer Journal* 2016; 6(1): e378.

116. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, MD, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht L, Offidani M, Hungria V, **Spencer A**, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3 study. *Lancet Oncology* 2016; 17(1): 27-38.

117. Doan TN, Kirkpatrick CM, Walker P, Slavin MA, Ananda-Rajah MR, Morrissey CO, Urbancic KF, Grigg A, **Spencer A**, Szer J, Seymour JF, Kong DC. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. *Journal of Antimicrobial chemotherapy* 2016; 71(2): 497-505.

118. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, **Spencer A**, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel J. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. *Cancer* 2016; 122: 2050-6.

119. Lee WTY, Cain JE, Cuddihy A, Johnson J, Dickinson A, Yeung K, Kumar B, Johns TG, Watkins N, **Spencer A,** St John JC. Mitochondrial DNA plasticity is an essential inducer of tumorigenesis. *Cell Death Discovery* 2016; 2, 16016; doi:10.1038/cddiscovery.2016.16

120. Levin N, **Spencer A**, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, Reich SD, Richardson P, Trikha M. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. *British Journal of Haematology* 2016; 174: 711-20.

121. Lipton A, Smith MR, Fizazi K, Stopeck A, Henry D, Brown JE, Shore N, Saad F, **Spencer A**, Zhu L, Warner D. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. *Clinical Cancer Research* 2016 clincanres.3086.2015 [Epub ahead of print]

122. Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, Cannell PK, Reich SD, Trikha M, **Spencer A**. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies including Multiple Myeloma: Study NPI-0052-102 Final Results. *Clinical Cancer Research* 2016; 22: 4559-4566.

123. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, **Spencer A,** Sonneveld P. Daratumumab, bortezomib and dexamethasone for relapsed or refractory myeloma. *New England Journal of Medicine* 2016; 375(8): 754-766.

124. Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, Khaw SL, Lessene G, **Spencer A**, Herold MJ, Roberts AW, Huang DCS. Hierachy for targeting pro-survival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. *Blood*-2016-03-704908 [Epub ahead of print]

125. Liu H, Pattie P, Chandrasekara S, **Spencer A**, Dear A. Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies. *Oncology Letters* 2016; 12: 2175-2180.

126. Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, **Spencer A.** Design and development of the Australian and New Zealand myeloma and related diseases registry. *BMC Medical Research Methodologies* 2016; 16(1): 151

127. Coutsouvelis J, Avery S, Dooley M, Kirkpatrick C, **Spencer A.** Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation. *Cancer Treatment Reviews* 2016; 50: 200-204.

128. Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, **Spencer A,** Wei A. The mTOR inhibitor everolimus in combination with azacytidine in patients with relapsed/refractory acute myeloid leukemia: A phase Ib/II study. *Oncotarget* 2016; 8(32): 52269-52280.

129. Mithraprabhu S, Khong T, Ramachandran M, Chow A, Klarica D, Hocking J, Mai L, Walsh S, Broemeling D, Marziali A, Kalff A, Wiggin M, Durie B, **Spencer A**. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. *Leukemia* 2017; 31: 1695-1705.

130. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Cluse LA, Beavis PA, Darcy KP, Martin BP, **Spencer A,** Sadovnik I, Bauer K, Valent P, Traunbauer AK, BradnerJE, Zuber J, Shortt J, Johnstone RW. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 through direct effects on BRD4. *Cell Reports* 2017; 18(9):2162-74.

131. Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, **Spencer A**. Beta-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitors in multiple myeloma. *Molecular Cancer Therapeutics* 2017; 16(9): 1765.

132. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, **Spencer A**, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg S, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *British Journal of Haematology* 2017 May 9. doi: 10.1111/bjh.14733

133. Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, **Spencer A**, Ritchie D, Cheng AC, Samri A, Carcelain G, Autran B, Lewin SR. Identifying Cytomegalovirus (CMV) complications using the Quantiferon-CMV assay after Allogeneic Hematopoietic Stem Cell Transplantation. *Journal of Infectious diseases* 2017 Apr 18. doi: 10. 1093/infdis/jix192.

134. Quach H, White D, **Spencer A**, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. *Cancer Chemother Pharmacol* 2017 Apr 19. doi:10.1007/s00280-017-3287-8.

135. Yong MK, Ananda-Rajah M, Cameron PU, Morrissey CO, **Spencer A**, Ritchie D, Cheng AC, Lewin SR, Slavin M. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: A multicenter study in the current era of viral load monitoring. *Biology of Blood and Marrow Transplantation* 2017; Aug 7. doi: 10.1016/j.bbmt2017.07.025.

136. Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua DM, Weisel K, **Spencer A**, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: Secondary analysis of the phase 3 Endeavour study. *Leukemia and Lymphoma* 2017; Sep 22. doi. 10.1080/10428194.2017.1376743

137. **Spencer A,** Harrison S, Laubach J, Zonder J, Badros A, Bergin K, Khot A, Zimmerman T, Anderson K, MacLaren A, Reich SD, Trikha M, Richardson P. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): Final study results. *British Journal of Haematology* 2017; 180(1): 41-51

138. Coutsouvelis J, Avery S, Dooley M, Kirkpatrick C, **Spencer A**. Defibrotide for the treatment of sinusoidal obstruction syndrome: Evaluation of response to therapy and patient outcomes. *Journal of Supportive Care in Cancer* 2017; 26(3): 947-955.

139. Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, **Spencer A**, Ritchie D, Lewin SR. Low T-Cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation. *Frontiers in Immunology* 2017; 8: 1506.

140. Schlenk RF, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, **Spencer A**, Candoni A, Gil JS, Berkowitz N, Weber HJ, Ottmann O. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. *Haematologica* 2018; 103(1): e25-28.doi:10.3324/haematol.2017.172411

141. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, **Spencer A,** Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as Treatment for Chemoimmunotherapy-Refractory Patients with Follicular Lymphoma: Results from the Open-Label, Multicenter, Phase II DAWN Study. *Journal of Clinical Oncology* 2018; 36(23): 2405-2412.

142. Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C,

Offidani M, **Spencer A**, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M. Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis. *JAMA Oncology* 2018 Aug 9. doi: 10.1001/jamaoncol.2018.2961. [Epub ahead of print]

143. Trezise S, Karnowski A, Fedele PL, Mithraprabhu S, Liao Y, D'Costa K, Kueh AJ, Hardy MP, Owczarek CM, Herold MJ, **Spencer A**, Shi W, Willis SN, Nutt SL, Corcoran LM. Mining the plasma cell transcriptome for novel cell surface proteins. *Int J Mol Sci* 2018 Jul 24;19(8). pii: E2161. doi: 10.3390/ijms19082161.

144. Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, **Spencer A**, Boccadoro M, Bringhen S. Treatment intensification with autologous stem cell transplantation and lenalidom ide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response. *Clin Lymphoma Myeloma Leuk* 2018; 18(8): 533-540.

145. Mithraprabhu S, Sirdesai S, Chen M, Khong T, **Spencer A.** Circulating tumour DNA analysis for tumour genome characterization and monitoring disease burden in extramedullary multiple myeloma. *Int J Mol Sci* 2018; 19(7): pii: E1858. Doi: 10.3390/ijms1907 1858

146. Yuen HLA, Low MSY, Fedele P, Kalff A, Walker P, Bergin K, Coutsouvelis J, Grigoriadis G, **Spencer A.** DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. *Leukemia and Lymphoma* 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1454595. [Epub ahead of print]

147. **Spencer A,** Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JL, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. *Haematologica* 2018;103(12):20079-2087.

148. de Silva HD, French RA, Korem M, Orlowski E, Curtis DJ, **Spencer A,** Avery S, Patil S, Morrissey CO. Contemporary analysis of functional immune recovery to opportunistic and vaccine-preventable infections after allogeneic haemopoietic stem cell transplantation. *Clin Transl Immunology* 2018; 7(10): e1040.

149. Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, **Spencer A**, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. *British Journal of Haematology* 2018 Nov 20. doi: 10.1111/bjh.15679. [Epub ahead of print]

150. Weisel K, Sonneveld P, **Spencer A**, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: A network meta-analysis. *Leukemia and Lymphoma* 2018 Nov 8:1-12. doi: 10.1080/10428194.2018.1466392. [Epub ahead of print].

151. Savvidou I, Khong T, **Spencer A.** Overcoming innate resistance to beta-catenin inhibitor Tegavivint by manipulating autophagy in multiple myeloma. *Medical Research Archives* 2019; 7(12): 1-21

152. Liu H, Hu Y, Rimoldi R, Von Hagt C, Khong EWC, Lee N, Fleming S, **Spencer A**, Dear AE. Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling. *Oncology Letters* 2019; 17(2): 2543.

153. Kalff A, Khong T, Mithraprabhu S, Bergin K, Reynolds J, Bowen K, Thakurta A, Guzman R, Wang M, Couto S, Ren Y, **Spencer A.** Oral azacytidine (cc-486) in combination with lenalidomide and

dexamethasone in advanced, lenalidomide-refractory Multiple Myeloma (ROAR Study). *Leukemia and Lymphoma* 2019; 60(9): 2143-2151.

154. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, **Spencer A,** Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomized, placebo-controlled phase 3 trial. *Lancet* 2019; 393: 253-264.

155. Horvath N, **Spencer A,** Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. *Leukemia and Lymphoma* 2019; 19: 1-12.

156. Soekojo CY, Wang G, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, Mel S, Koh LP, Tan K, Oooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, **Spencer A,** Gopalakrishnan SK, Chng WJ. Role of conventional karyotyping in multiple myeloma in the era of modern-day treatment and FISH analysis. *Clinical Lymphoma Myeloma and Leukemia* 2019; 19: e470-e477.

157. **Spencer A**, Walker P, Asvadi P, Campbell DH, Reed K, Herbert BR, Breen EJ, Copeman MC, Dunn RD. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma. *Blood cancer J.* 2019:9: 58

158. Mithraprabhu S, Hocking J, Ramachandran M, Choi K, Klarica D, Khong T, Reynolds J, **Spencer A**. DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. *Cancers* 2019: 11: E917

159. Chen M, Mithraprabhu S, Ramachandran M, Choi K, Khong T, **Spencer A**. Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients. *Cancers* 2019: 11: e887

160. Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, **Spencer A.** Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. *Clinical Lymphoma Myeloma and Leukemia* 2019; 19: e415-e424.

161. Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, **Spencer A,** Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V. INSIGHT MM: A large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. *Future Oncology* 2019; 15(13): 1411-1428.

162. Mithraprabhu S, Morley R, Khong T, Kalff A, Bergin K, Hocking J, Savvidou I, Bowen KM, Ramachandran M, Choi K, Wong BKL, Reynolds J, **Spencer A.** Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. *Leukemia* 2019; 33(8): 2022-2033.

163. Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, **Spencer A,** Hájek R, Boccadoro M, Gay F. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. *Cancers* 2019; 11. pii: E1735. doi: 10.3390/cancers11111735.

164. Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, **Spencer A.** Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. *Clinical Lymphoma, Myeloma and Leukemia* 2019; Oct 9: S2152-2650(19)32010.

165. Mateos MV, **Spencer A**, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. *Haematologica* 2020: 105(2); 468-477.

166. Landgren O, Chari A, Cohen YC, **Spencer A**, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C Cavo M, van de Donk N, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Daratumumab monotherapy for patient swith intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open label, multicenter, phase 2 study (Centaurus). *Leukemia* 2020: 34; 1840-1842.

167. Lee HC, Raje NS, Landgren O, Upreti VV, Jin Wang J, Avilion AA, Hu X, Rasmussen E,[7] Ngarmchamnanrith G, Fujii H, **Spencer A.** Phase 1 study of the anti-BCMA antibody-drug conjugate AMG224 in patients with relapsed/refractory multiple myeloma. *Leukemia* 2021; 35: 255-258

168. Norton SE, Julia KH Leman KHJ, Khong T, **Spencer A,** Fazekas de St Groth B, McGuire HM, Kemp R. Brick plots: An intuitive platform for visualizing multiparametric cell clusters. *BMC Informatics* 2020: 21(1); 145

169. Moore EM, King TA, Wood EM, Ruseckaite R, Klarica D, **Spencer A**, Ho PJ, Quach H, Prince HM, McQuilten ZK. Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. *Am J Hematol.* 2020:95(7); E178-E181.

170. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, **Spencer A**, Boccadoro M, Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre randomized, open label, phase 3 study. *Lancet Haematology*. 2020: 7(6); e456-e468.

171. Rees MJ, **Spencer A**, Browett P, Alvaro F, Purtill D, Crawford J, Milliken S, Lai H, Pullon H, Grigg A. High rate of durable remissions post autologous stem cell transplantation for coreo-binding factor acute myeloid leukaemia in second complete remission. Bone Marrow Transplant 2020 (in press).

172. Schjesvold FH, Richardson PG, Attal M, Facon T, Alegre A, **Spencer A**, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S. Isatuximab plus Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. *Haematologica* 2021; 106: 1182-1187.

173. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, **Spencer A**, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology 2020; 99(8): 1793-1804post-transplant ixazomib maintenance in multiple myeloma. *Annals of Hematology* 2020; 99(8): 1793-1804

174. Weisel K, **Spencer A**, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min

CK, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos MV. Daratumumab, bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. *J Hematol Oncol* 2020; 13: 115.

175. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, **Spencer A**, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide and dexamethasone in RRMM: final overall survival results from the phase 3 randomised ELOQUENT-2 study. *Blood Cancer J.* 2020; 10: 91.

176. Lwin Y, Kennedy G, Gottlieb D, Kwan J, Ritchie D, Szer J, Milliken S, Browett P, **Spencer A**, Butler A, Bardy P, Greenwood M, Perera T, He S, McEwan A, Larsen S, Lai H, Purtill D, Tran S, Aarons D, Hamad N. Australasian trends in allogeneic stem cell transplantation for myelofibrosis in the molecular era: A retrospective analysis from the Australasian Bone Marrow Recipient Registry. Biol Blood Marrow Transplant. 2020; 26: 2252-2261.

177. Das TP, KIpp DA, Kliman DS, Patil SS, Curtis DJ, O'Brien ME, Swain MI, Widjaja JML, Cooke JL, Ziino MN, **Spencer A**. Important factors in implementation of lineage-specific chimerism analysis for routine use. *Bone Marrow Transplantation* 2021; 56: 946-948.

178. Reale A, Khong T, Mithraprabhu S, Savvidou I, Hocking J, Bergin K, Ramachandran M, Chen M, Dammacco F, Ria R, Silvestris F, Vacca A, Reynolds J, **Spencer A**. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leu Lymphoma 2021; 62: 337-347.

179. Loh JBE, Walker P, Avery S, Patil S, **Spencer A**, Wei A, Fleming S. Double trouble or silver lining? A case report of 2 patients with NPM1-mutated donor-derived acute myeloid leukaemia. Leuk Lymphoma 2021; 62: 489-491.

180. Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, **Spencer A.** Phase II trial of single-agent Panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma. Br J Haematol. 2021; 193: 160-170.

181. Tan J, Das T, Kliman D, Muirhead J, Gorniak M, Kalff A, Walker P, **Spencer A.** Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. *Bone Marrow Transplantation* 2021; 56: 1116-1125.

182. Cairns KA, Hall V, Martin GE, Griffin DWJ, Stewart JD, Khan SF, Abbott IJ, Meher-Homji Z, Morrissey CO, Sia C, Love J, Corallo CE, Bergin P, Sharma A, Gopal B, **Spencer A**, Peleg AY. Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review. *Transplant Infectious Disease* 2021; 23: e13510

183. Reynolds G, Stewart T, Harrison SJ, **Spencer A**, Teh BW. Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. *Leukemia & Lymphoma* 2021; 62: 1271-1274.

184. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, **Spencer A**, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. *Lancet Oncology* 2021; 22(1): 142-154

185. Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, **Spencer A**, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis NJ.Evaluation of Sustained Minimal Residual Disease Negativity With

Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021 Apr 1;39(10):1139-1149.

186. Hungria V, Beksac M, Weisel KC, Nooka AK, Masszi T, Spicka I, Munder M, Mateos MV, Mark TM, Qi M, Qin X, Fastenau J, **Spencer A**, Sonneveld P, Garvin W, Renaud T, Gries KS. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. Br J Haematol. 2021; 193: 561-569.

187. Reale A, Carmichael I, Xu R, Mithraprabhu S, Khong T, Chen M, Fang H, Savvidou I, Ramachandran M, Bingham N, Simpson RJ, Greening DW, **Spencer A.** Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells. Proteomics. 2021 Feb 12:e2000119. doi: 10.1002/pmic.202000119. Online ahead of print.

188. Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, **Spencer A**, Rhee FV, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Mar 26. doi: 10.2217/fon-2020-1225. Online ahead of print.

189. Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood E, **Spencer A**; Australian and New Zealand Myeloma and Related Diseases Registry. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clin Lymphoma Myeloma Leuk. 2021 Jan 30:S2152-2650(21)00034-3. doi: 10.1016/j.clml.2021.01.016. Online ahead of print.

190. Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, Romano A, Liberati AM, Mannina D, de Fabritiis P, Cascavilla N, Ruggeri M, Mina R, Patriarca F, Benevolo G, Belotti A, Gaidano G, Nagler A, Hájek R, **Spencer A**, Sonneveld P, Musto P, Boccadoro M, Gay F. Developing and Validating a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma (S-ERMM): Analysis from a Pooled Dataset of 2190 Patients. *Clinical Cancer Research* 2021 (in press)

191. Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, **Spencer A,** Usmani SZ, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Journal: *British Journal of Haematology* 2021 (in press)

192. Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, **Spencer A.** Real-world Utilisation of ASCT in Multiple Myeloma (MM): A report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Bone Marrow Transplantation* 2021 (in press)

193. Bergin K, Yuen F, Wallington-Beddoe C, Kalff K, Sirdesai S, Reynolds J, **Spencer A**. A phase 2 trial of continuous ixazomib, thalidomide and dexamethasone (ITd) for relapsed and/or refractory multiple myeloma (RRMM). AMaRC 16-02. *British Journal of Haematology* 2021 (in press)

194. Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, **Spencer A,** Delimpasi S, Hulin C, Sunami K, Facon T, Vlummens P, Yong K, Campana F, Inchauspé M, Macé S, Risse ML, van de Velde H, Richardson P. Subgroup analysis of ICARIA-MM in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. *British Journal of Haematology* 2021 (in press)

195. Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I, Pijpers L, Bjelosevic S, Williams T, Huskins SN, Kearney CJ, Devlin JR, Fan Z, Jabbari JS, Martin BP, Fareh M, Kelly MJ, Dupéré-Richer D, Sandow JJ, Feran B, Knight D, Khong T, **Spencer A**, Harrison SJ, Gregory G, Wickramasinghe VO, Webb AI, Taberlay PC, Bromberg KD, Lai A, Papenfuss AT, Smyth GK, Allan RS, Licht JD, Landau DA, Abdel-Wahab O, Shortt J, Vervoort SJ, Johnstone RW.

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. *Mol Cell* 2021 (in press)

196. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, **Spencer A**, Boccadoro M, Cavo M. Consolidation and maintenance in newly diagnosed multiple myeloma. *J Clin Oncol*. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.

197. Reale A, Khong T, Mithraprabhu, **Spencer A.** Translational potential of RNA derived from extracellular vesicles in multiple myeloma. *Front Oncol*. 2021 Aug 27;11:718502. doi: 10.3389/fonc.2021.718502. eCollection 2021.

198. Wiltshire K, Kalff A, Morrissey CO, Griffin D, Patil S, Spring S, **Spencer A,** Kliman D. SARS-CoV-2 infection in autologous stem cell transplantation. *Intern Med J*. 2021 Aug;51(8):1321-1323. doi: 10.1111/imj.15263.

199. Cavo M, San-Miguel JFF, Usmani SZ, Weisel KC, Dimopoulos MAA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria VTM, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar SK, van de Donk NWCJ, Sonneveld P, **Spencer A**, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi NC.Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. *Blood*. 2021 Jul 21:blood.2021011101. doi: 10.1182/blood.2021011101.

200. Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, **Spencer A.** Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). *Leuk Lymphoma*. 2021 Dec;62(12):2981-2991. doi: 10.1080/10428194.2021.1948030. Epub 2021 Jul 15.

201. Nikesitch N, Rebeiro P, Ho LL, Pothula S, Wang XM, Khong T, Quek H, **Spencer A,** Lee CS, Roberts TL, Ling SCW. The role of chaperone-mediated autophagy in bortezomib resistant multiple myeloma. *Cells* 2021 Dec;10(12):3464.

202. Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, **Spencer A**. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). *Haematologica.* 2022 Jan:107(1):321-325.

203. Coutsouvelis J, Corallo C, **Spencer A,** Avery S, Dooley M, Kirkpatrick C. A meta-analysis of palifermin efficacy for rhe management of oral mucositis in patients with solid tumours and haematological malignancy. *Critical Reviews in Oncology & Hematology* 2022 Jan; 103606. doi: 10.1016. Online ahead of print.

204. Savvidou I, Khong T, Whish S, Carmichael I, Sepehrizadeh T, Mithraprabhu S, Horrigan SK, de Veer M, **Spencer A.** Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. *Cancers* 2022;14,840. https://doi.org/ 10.3390/cancers14030840.

205. Minnie SA, Waltner OG, Ensbey KS, Olver SD, Collinge AD, Sester DP, Schmidt CR, Legg SR, Takahashi S, Nemychenkov NS, Sekiguchi T, Driessens G, Zhang P, Koyama M, **Spencer A**, Holmberg LA, Furlan SN, Varelias A, Hill GR. TIGIT inhibition and lenalidomide synergistically promote anti-myeloma immune responses after stem cell transplantation in mice. *J Clin Invest* 2022 Dec 13:e157907.

206. **Spencer A**, Samoilova O, Chng WJ, Labotka R, Li C, Wu KW, Saxena N, Yan X, Lee JH, Beksac M. Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma

patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial. *EJHaem* 2022; 3(4): 1241-1251.

207. Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, **Spencer A.** Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. *J Clin Oncol* 2022 Nov 22: JCO2102734

208. Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald EJ, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, **Spencer A**. The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. *Br J Haem* 2022 Nov . doi: 10.1111/bjh.18536

209. Minnie SA, Waltner OG, Ensbey KS, Nemychenkov NS, Schmidt CR, Bhise SS, Legg SRW, Campoy G, Samson LD, Kuns RD, Zhou T, Huck JD, Vuckovic S, Zamora D, Yeh A, **Spencer A**, Koyama M, Markey KA, Lane SW, Boeckh M, Ring AM, Furlan SN, Hill GR. Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity. *Sci Immunol* 2022; 7(76):eab03420.

210. Dillon HT, Saner NJ, Ilsley T, Kliman D, **Spencer A**, Avery S, Dunstan DW, Daly RM, Fraser SF, Owen N, Lynch BM, Kingwell BA, La Gerche A, Howden EJ. Preventing the adverse cardiovascular consequences of allogeneic stem cell transplantation with a multi-faceted exercise intervention: the ALLO-Active trial protocol. *BMC Cancer* 2022; 22(1):898.

211. McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, **Spencer A**. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Br J Haem* 2022;198(5):830-837.

212. Chen M, Xu R, Zhang J, **Spencer A**, Simpson R. Editorial: Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma. *Front Oncol* 2022;12:946160.

213. Nguyen PC, Muirhead J, Tan J, Kalff A, Bergin K, Walker P, **Spencer A.** Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience. *Intern Med J* 2022;52(7):1263-1267.

214. Turner R, Kalff A, Bergin K, Gorniak M, Fleming S, **Spencer A.** The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. *Front Oncol* 2022;12:820605.

215. Coutsouvelis J, Dooley M, Kirkpatrick CM, Avery S, Hopkins R, **Spencer A.** Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. *Bone Marrow Transplant* 2022;57(8):1329-1331.

216. Moore EM, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, George A, Baker B, Chan H, McQuilten ZK, Wood EM, **Spencer A**. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Clin Lymphoma Myeloma Leuk* 2022;22(8):e762-769

217. Kliman D, Tran S, Kennedy G, Curley C, McLean A, Gottlieb D, Kwan J, Ritchie D, Chee L, **Spencer A**, Purtill D, Bardy P, Larsen S, Chien N, Perera T, Greenwood M, Hamad N, Moore J. The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. *Bone Marrow Transplant* 2022;57(6):982-989

218. Rees MJ, Panigrahi A, Harrison SJ, **Spencer A**, Khong T, Gibbs S, Hocking J, Grigg A, Zantomio D. The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. *Bone Marrow Transplant* 2022;57(6):1001-1003

219. Zantomio D, Bayly E, Wong K, **Spencer A**, Ritchie D, Morgan S, Kelsey G, Dennington PM. Centre-based comparison of double versus single prevention strategy on transfusion-transmitted cytomegalovirus in at-risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus-seronegative ordering practises. *Intern Med* 2022 Mar 23. Doi:10.1111/imj.15751

220. Weisel K, Nooka AK, Terpos E, **Spencer A**, Goldschmidt H, Dirnberger F, DeCosta L, Yusuf A, Kumar S. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. *Leuk Lymphoma* 2022;63(8):1887-1896

221. Schjesvold F, Richardson PG, Facon T, Alegre A, **Spencer A**, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, Van de Velde H, Bensfia S, Bringhen S. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. *Haematologica* 2022;107(3):774-775.

222. Mithraprabhu S, Reynolds J, Turner R, Quach H, Horvath N, Kerridge I, Kalff A, Bergin K, Hocking J, Yuen F, Khong T, Durie BM, **Spencer A.** Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma. *Blood Cancer Journal* 2023;13(1):25

223. Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, **Spencer A**, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. Rates of influenza and pneumococcal vaccination and correlation with survival in multiple myeloma patients. *Clin Lymphoma Myeloma Leuk* 2023;23(3):e171-e181

224. Coutsouvelis J, Kirkpatrick CM, Dooley M, **Spencer A**, Kennedy G, Chau M, Huang G, Doocey R, Copeland TS, Do L, Bardy P, Kerridge I, Cole T, Fraser C, Perera T, Larsen SR, Mason K, O'Brien TA, Shaw PJ, Teague L, Butler A, Watson AM, Ramachandran S, Marsh J, Khan Z, Hamad N. Incidence of sinusoidal obstruction syndrome/veno-occlusive disease and treatment with defibrotide in allogeneic transplantation: A multicenter Australian registry study. *Transplant Cell Ther* 2023;29(6):383

225. Das TP, North D, Fleming SA, Tan JLC, Ivey A, Cummings NJ, **Spencer A**, Patil SS, Widjaja JML, Swain MI, Bourke C, O'Brien ME, Kliman DS, Curtis DJ. Peripheral blood cD34 donor chimerism has greater utility than CD3 for detecting relapse after after allogeneic stem cell transplantation for acute myeloid leukaemia or myelodysplastic syndrome. *Transplant Cell Ther* 2023;S2666-636.

226. Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, **Spencer A**, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H. Preclinical discovery and initial clinical data of WVT078, a BCAM x CD3 bispecific antibody. *Leukemia* 2023;37(6):1349-1360.

227. Lamanuzzi A, Saltarella I, Reale A, Melaccio A, Solimando AG, Altamura C, Tamma G, Storlazzi CT, Tolomeo D, Desantis V, Mariggiò MA, Desaphy JF, **Spencer A**, Vacca A, Apollonio B, Frassanito MA. Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications. *Biomedicines* 2023;11(5):1400

228. San-Miguel J, Dhakal B, Yong K, **Spencer A**, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. *N Engl J Med* 2023; doi:10.1056/NEJMoa2303379.

229. **Spencer A,** Kalff A, Shortt J, Quach H, Wallington-Gates C, Reynolds J, Walker P, Harrison SJ, Dunn R, Wellard C. A sequential cohort study evaluating single-agent KappaMab and KappaMab combined

with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). *Br J Haem* 2023;202(4):801-811

230. Mithraprabhu S, Reynolds J, Quach H, Horvath N, Kerridge I, Khong T, Durie BM, **Spencer A**. Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. *Haematologica* 2023; Sep 28. doi: 10.3324/haematol.2023.283831

231. **Spencer A,** Moreau P, Mateos MV, Goldschmidt H, Suzuki K, Levin MD, Sonneveld P, Orlowski RZ, Yoon SS, Usmani SZ, Weisel K, Reece D, Ahmadi T, Pei H, Mayo WG, Gai X, Carey J, Bartlett JB, Carson R, Dimopoulos MA. Daratumumab in myeloma patients with early or late relapse after initial therapy: Subgroup analysis of CASTOR and POLLUX. *Blood Advances* 2023. doi: 10.1182/bloodadvances. 2023010579

232. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, **Spencer A**, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2023. Doi: 10.1056/NELMoa2312054.

233. Norton SE, Khong T, Ramachandran M, Highton AJ, Ward-Hartstonge KA, Shortt J, **Spencer A**, Kemp RA. Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma. *Clin Transl Immunology* 2023;12(12):e1478.

234. Lim SL, Wellard C, Moore E, Harrison SJ, Quach, Ho J, Rajagopal R, **Spencer A.** Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ Myeloma and Related Diseases Registry. *Intern med J* 2023 doi: 10.1111/imj.16277

235. Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, **Spencer A**. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). *Br J Haem* 2024 Online ahead of print.

236. Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, **Spencer A.** Daratumumab, cyclophosphamide, bortezomib and dexamethasone for transplant ineligible myeloma: AMaRC 03-16. *Blood Adv* 2024; 8(14): 3721-3730.

237. Ho PJ, **Spencer A**, Mollee P, Bryant CE, Enjeti AK, Horvath N, Butcher BE, Trotman J, Gibbs S, Joshua DE. Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment – An ALLG trial of carfilzomib-dexamethasone therapy in front-line and relapse. *Clin Lymphoma Myeloma Leuk* 2024.doi.org?101016/j.clml2024.04.001.

238. Aoki N, Chen PY, Chen W, Chng WJ, Gan GG, Goh YT, Hou J, Huang J, Kim K, Lee JJ, Lu J, McQuilten ZK, Min CK, Moore E, Oliver L, Waters NA, Wellard C, Wood EM, Yeh SP, **Spencer A**. The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). *BMC Med Res Methodol* 2024; 24(1): 102

239. Zeissig MN, Hewett DR, Mrozik KM, Panagopoulos V, Wallington-Gates CT, **Spencer A**, Dold SM, Engelhardt M, Vandyke K, Zannettino ACW. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leuk Res 2024 Apr; 139:107469. Doi: 10.1016

240. Tan JLC, Curtis DJ, Muirhead J, Swain MI, Fleming SA, Cirone B, O'Brien ME, Wong SM, Inam S, Patil S, **Spencer A**. CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in

Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome. *Clinical Lymphoma, Myeloma & Leukemia* 2024.doi.org?101016/j.clml2024.07.006

241. Minnie SA, Waltner OG , Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, Schmidt CR, Legg SRW, Comstock M, Boiko JR, Nelson E, Bhise SS, Wilkens AB, Koyama M, Dhodapkar MV, Chesi M, Riddell SR, Green DJ, **Spencer A**, Furlan SN, Hill GR. TIM-3^+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Science Immunology April 2024; 9(94)

242. Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, **Spencer A**, McQuilten ZK. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. *PLoS One* 2024: 19(8); e0308812

243. Chai KL, Wellard C, Thao L, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim K, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso AC, Wong KS, Yoon SS, **Spencer A**, Wood EM, McQuilten ZK. Variation in immunoglobulin use and impact on survival in myeloma. *EJHaem* 2024: 5(4); 690-697.

244. Dillon HT, Saner NJ, Ilsey T, Kliman DS, Foulkes SJ, Brakenridge CJ, **Spencer A**, Avery S, Claus P, Dunstan DW, Daly RM, Fraser SF, Owen N, Lynch BM, Kingwell BA, La Gerche A, Howden EJ. Preventing allogeneic stem cell transplant-related cardiovascular dysfunction: ALLO-Active Trial. *Circulation* 2024; doi: 10.1161/CIRCULATIONAHA.124.070709

245. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, van de Donk NWCJ, Katodritou E, Schjesvold F, Balari AS, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, **Spencer A**, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P. Aplain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide and dexamethasone for treating newly diagnosed multiple myeloma. Future Oncology 2024; Sep 17: 1-21

246. Zhao J, Khong T, Gorniak M, Khaled A, McDonald Z, Reynolds J, Mithraprabhu S, Bingham N, Lim SL, Wong D, Johnston A, Motorna O, Murphy N, Quach H, Yang L, **Spencer A.** Comparison of EasyM, a clonotypic mass spectrometry assay and EuroFlow minimal residual disease assessment in multiple myeloma. *Haematologica* 2024 (in press).

247. Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, **Spencer A,** Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten Z, Chen F, Quach H. Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia* 2024 Nov 9;S2152-2650.

248. Landgren CO, Chari A, Cohen YC, **Spencer A**, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC. Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: Final analysis of CENTAURUS. *Blood* 2024 Dec 9: doi: 10.1182/blood.2024025897.

249. Olaisen C, Røst LM, Sharma A, Søgaard CK, Khong T, Berg S, Jang M, Nedal A, **Spencer A**, Bruheim P, Otterlei M. Multiple myeloma cells with increased proteasomal and ER stress are hypersensitive to ATX-101, an experimental peptide drug targeting PCNA. *Cancers* 2024; 16(23): 3963.

250. Bingham N, Shah J, Wong D, Lim SL, Bergin K, Kalff A, Reale A, Khong T, Mithraprabhu S, **Spencer A.** Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma. Blood Cancer J 2025; 15(1): 5

251. Kazzi C, Simpson T, Abbott C, Wronski M, Seery N, Tan TH, Wesselingh R, Ko K, Wong SM, Inam S, Tam C, Fleming S, O'Brien TJ, Alpitsis R, **Spencer A**, Malpas C, Monif M. Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series. *BMJ Neurol Open* 2025; 7(1): e000927.doi: 10.1136/bmjno-2024-000927.

252. Gong JN, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang LP, Fedele PL, Low MS, Anderson MA, Riffkin CD, White CA, Lan P, Lessene G, Herold MJ, Strasser A, **Spencer A**, Grigoriadis G, Wei AH, van Delft MF, Roberts AW, Huang DCS. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins. *Cell Death & Differentiation* 2025; 32(8):1382-1396.

253. Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, **Spencer A**, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman JL. Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. *Clinical Lymphoma Myeloma & Leukemia* 2025; 25(10(:746-758.

254. Ashby M, Fleming S, **Spencer A**, Woollett A, Wright T. Filling the gaps to empower regional centres to manage myelodysplastic syndrome and acute myeloid leukemia leading to wider cancer healthcare delivery and access to clinical trials. *Internal Medicine Journal* 2025; 55(5):722-727.

255. Barge L, Tran S, Kennedy G, Ritchie D, Gottlieb D, Milliken S, **Spencer A**, Purtill D, Perera T, Doocey R, Larsen S, Butler A, Bardy P, Greenwood M, Durrant S, Curley C, Stewart C, Tam C, Balendran S, Di Ciaccio PR, Patil S, Han MH, Hamad N. Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era. *Internal Medicine Journal* 2025; 55(7):1105-1113.

256. Ailawadhi S, Špička I, **Spencer A**, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J, Goldschmidt H, Zhang R, Sémiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. *Journal of Clinical Oncology* 2025; 43(27):3056.

257. Zhao S, Wellard C, Moore EM, **Spencer A**, Quach H, Ho PJ, McDonald EJ, Mollee P, Harrison SJ, Augustson B, Wood EM, McQuilten ZK, Rajagopal R. Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry. *Clinical Lymphoma Myeloma & Leukemia* 2025; S2152-2650(25)00269-1.

258. Hughes E, Latham S, Kuss B, Grist S, Hall R, Khong T, Gorniak M, **Spencer A**, Tam C, Mulligan S, Bailey S, Sartor M, Carney D, Cull G, Gottlieb D, Morley A. HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma. *International Journal of Molecular Science* 2025; 26(16):7720

259. Kazzi C, Simpson T, Wronski M, Seery N, Wesselingh R, Tan TH, Ko KY, Pearce DJ, Abbott C, Li J, Griffith SP, Wong SM, Westworth M, Inam S, Tam CS, Fleming S, Van Der Walt A, O'Brien TJ, Alpitsis R, **Spencer A**, Malpas CB, Sanfilippo P, Monif M. CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy. *British Journal of Haematology* 2025; 207(4):1495-1503.

260. Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, **Spencer A**, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P. Circulating tumor cells predict myeloma outcomes in patients

treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. *Blood* 2025; doi 10.1182/blood.2025030113.

261. Li J, Melsew Y, Wellard C, Moore EM, Ho PJ, Quach H, Harrison SJ, Rajagopal R, Augustson B, Wood EM, **Spencer A.** New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR). *Clinical Lymphoma Myeloma & Leukemia* 2025; doi 10.1016/j.clml.2025.10.013.

262. Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, **Spencer A**, McQuilten ZK. A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. *Pharmacoeconomics* 2025; doi 10.1007/s40273-025-01554-4

263. Lim SL, Wellard C, Rajagopal R, Harrison SJ, Khot A, Quach H, Ho PJ, Moore E, Wood E, **Spencer A**. No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

264. **Spencer A**, Gavriatopoulou M, Coriu D, Lysén A, Gutiérrez NC, Escalante F, Eugenia Fantl DB, Hájek R, Seguro F, Kaur G, Bittencourt R, Kinda SB, Chu MP, Safah H, Martinez-Lopez J, de Queiroz Crusoé E, Cordeiro de Farias DL, Offidani M, Askari E, Sevindik ÖG, Maisnar V, Teng CL, Hughes O, Taylor R, Lehn K, Feng D, Thiébaut-Millot R, Li X, Murray L, Jung P, Rossi EL, Kongpachith S, Nichol A, Ross JA, Hader C. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis. *Blood Advances* 2025; 9(22):5814-5827.

265. Kazzi C, Griffith SP, Ko KY, Pearce DJ, Wronski M, Seery N, Wesselingh R, Tan TH, Simpson T, Abbott C, Li J, Cole E, Westworth M, Inam S, Rushen T, Parsons S, Melitsis L, Wong SM, Butzkueven H, Van Der Walt A, Nandurkar H, Tam CS, Fleming S, O'Brien T, Alpitsis R, **Spencer A**, Malpas CB, Monif M. Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy. *Transplant & Cellular Therapy* 2025; doi 10.1016/j.tct.2025.11.031.

<u>Reviews, Editorials and Letters</u>

266. **Spencer A**, O'Brien SG, Goldman JM [Annotation]. Options for therapy in Chronic Myeloid Leukaemia. *British Journal of Haematology* 1995; 91, (1): 2-7.

267. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani A, Gay F, Moreau P, Waager A, **Spencer A**, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma – Ten years later. *Blood* 2008; 111: 3968-3977.

268. **Spencer A,** Prince HM, Roberts A. Reply to Cavo: Thalidomide should be the comparator for alternative novel post-ASCT strategies in myeloma. *Journal of Clinical Oncology* 2009; 27: e188

269. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, **Spencer A**, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia* 2009; 23: 1716-1730.

270. Engelhardt M, Kleber M, Udi J, Wasch R, **Spencer A**, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A. Consensus statement from European experts on the diagnosis,

management and treatment of multiple myeloma: From standard therapy to novel approaches. *Leukemia & Lymphoma* 2010; 51: 1424-1443.

271. Mithraprabhu S, Grigoriadis G, Khong T, **Spencer A.** Deacetylase inhibition in myeloproliferative neoplasms. (Invited Review) *Investigational New Drugs* 2010; 28 Suppl 1: S50-7

272. **Spencer A.** Inside Blood Commentary – 'No longer the poor relations'. (Invited Commentary) *Blood* 2010; 11: 3685-3686.

273. Sushrut P, Coutevoulis J, **Spencer A.** Asparaginase in the management of adult acute lymphoblastic leukaemia: is it used appropriately? *Cancer Treatment Reviews* 2011; 37: 202-207

274. Engelhardt M, Udi J, Kleber M, **Spencer A**, Rocci A, Knop S, Bruno B, Bringhen S, Perez-Simon JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hajek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leukemia & Lymphoma* 2010; 51: 2006-2011.

275. Monaghan K, **Spencer A.** The role of the microenvironment in multiple myeloma. *Asia-Pacific Journal of Oncology and Hematology* 2011; 2: 49-56.

276. Quach H, Prince HM, **Spencer A.** Managing multiple myeloma in the elderly: are we making progress? *Expert Reviews in Hematology* 2011; 4(3): 301-15.

277. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies FE, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, **Spencer A**, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). *Blood* 2011; 118(17): 4519-29.

278. Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, **Spencer A**, Sonneveld P, San Miguel JF. How to manage neutropenia in Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia* 2011; 12 (1): 5-11.

279. Ludwig H, Durie BGM, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, **Spencer A,** Anderson KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG Consensus on maintenance therapy in multiple myeloma. *Blood* 2012 (in press).

280. Quach H, Kalff A, **Spencer A.** Lenalidomide in multiple myeloma: Current status and future potential. *American Journal of Hematology* 2012; 87 (12): 1089-1095.

281. Kalff A & **Spencer A.** The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. *Blood Cancer Journal* 2012: 2 (9) e89.

282. Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanchez R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, **Spencer A**, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD. International Myeloma Working Group recommendations for the treatment of multiple myeloma related bone disease. *Journal of Clinical Oncology* 2013; 31 (18): 2347-2357.

283. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Leow CCY, Gerondakis S, **Spencer A**. *Blood Cancer Journal* 2013; 3 (3), e105.

284. Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, **Spencer A**, Szer J, Talaulikar D, To B, Zannettino A, Prince HM. Management of systemic light chain (AL) amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal* 2014 Aug 28. doi: 10.1111/imj.12566.

285. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R,

Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, **Spencer A**, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International myeloma working group consensus statement for the management, treatment and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *Journal of Clinical Oncology* 2014; 32(6): 587-600.

286. Quach H, Joshua D, Ho JP, Szer J, **Spencer A**, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (MSAG). *Internal Medicine Journal* 2015; 45(3): 335-343.

287. Quach H, Joshua D, Ho JP, Szer J, **Spencer A**, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (MSAG). *Internal Medicine Journal* 2015; 45(1): 95-105.

288. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, **Spencer A**, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Cavo M, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, Miguel JS, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: a report from IMWG. *Journal of Clinical Oncology* 10.1200/JCO.2015.61.2267

289. Hocking J, Mithraprabhu S, Kalff A, **Spencer A.** Liquid biopsies for liquid tumours: emerging potential of circulating free nucleic acid evaluation for the management of haematologic malignancies. *Cancer Biology and Medicine* 2016; 13: 215-225.

290. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, **Spencer A**, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimuzu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar V, San Miguel J, Avet –Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *The Lancet Oncology* 2016; 17(8): e328-346.

291. **Spencer A** & Mithraprabhu S. Epigenetics in the biology and treatment of multiple myeloma. *European Oncology and Haematology* 2016; 12(2): 96-102.

292. Bergin K, McQuilten Z, Moore E, Wood E, **Spencer A**. Myeloma in the real world: What's really happening? *Clinical Lymphoma, Myeloma and Leukemia* 2016; 17(3): 133-144.

293. Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, **Spencer A,** Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A. Bisphosphonate guidelines for the treatment and prevention of myeloma bone disease. *Internal Medicine Journal* 2017; 47(8): 938-951.

294. Bingham N. Reale A, **Spencer A**. An evidence-based approach to myeloma bone disease. *Curr Hematol Malig Re*. 2017; 12(2): 109-118.

295. Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, **Spencer A,** Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zennettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM. Treatment of patients with Waldenstrom macroglobulinaemia; Clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal* 2017; 47(1): 35-49.

296. Mithraprabhu S & **Spencer A.** Circulating tumour DNA analysis in multiple myeloma. *Oncotarget* 2017; 8(53): 90610-90611.

297. Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Prince H, Mollee P, **Spencer A**, Ho J, Harrison SJ, Lee C, Augustson B, Daly J. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. *Internal Medicine Journal* 2018; 48(2): 210-220.

298. Rodda AE, Parker BJ, **Spencer A,** Corrie SR. Extending circulating tumour DNA analysis to ultralow abundance mutations: Techniques and challenges. *ACS Sens* 2018; 3(3): 540-560.

299. Savvidou I, Khong T, Alt K, **Spencer A.** The canonical Wnt/B-Catenin pathway as a therapeutic target in multiple myeloma. *Medical Research Archives* 2018; 6(7): 1-15.

300. Dimopoulos D, Jakubowiak A, McCarthy P, Orlowski R, Attal M, Blade J, Goldschmidt H, Weisel K, Ramasamy K, Zweegman S, **Spencer A**, Huang SY, Lu J, Sunami K, Iida S, Chng WJ, Holstein S, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson K. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. *Blood Cancer Journal* 2019 (in press).

301. Wei AH, Roberts AW, **Spencer A**, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A. Targeting MCL-1 in hematologic malignancies: Rationale and progress. *Blood Reviews* 2020 (in press).

302. Bingham N & **Spencer A.** The role of cfDNA and liquid biopsies in haematological conditions. *Cancer Drug Resistance* 2020 (in press).

303. Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, Hapgood G, **Spencer A**, Dickinson M, Latimer M, Johnston A, Armytage T, Lee C, Cochrane T, Berkhahn L, Weinkove R, Doocey R, Harrison SJ, Webber N, Lee HP, Chapman S, Campbell BA, Gibbs SDJ, Hamad N. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. *Internal Medicine Journal* 2020: 50(6); 667-679.

304. Hamad N, Gottlieb D, Ritchie D, Kennedy G, Watson AM, Greenwood M, Doocey R, Perera T, **Spencer A**, Wong E, O'Brien T, Shaw P, Conyers R, Cole T, Milliken S, Bardy P, Larsen S, Lai H, Butler A, Fraser C, Bajel A, Butler J, Kerridge I, Purtill D. Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement. *Internal Medicine Journal* 2020: 50(6); 774-775.

305. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, **Spencer A**, Suman VJ, Usmani SZ, McCarthy PL. Summary of the Fourth Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. *Biology of Blood and Marrow Transplantation* 2020;m26: e247-e255.

306. Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, **Spencer A**, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonisation in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia.* 2021; 35: 18-30

307. Mithraprabhu S, Chen M, Savvidou I, Reale A, **Spencer A.** Liquid biopsy: An evolving paradigm for the biological characterisation of plasma cell disorders. *Leukemia* 2021 (in press).

308. Berdeja JG, Laubach JP, Richter J, Stricker S, **Spencer A**, Richardson PG, Chari A. Panobinostat from bench to bedside; Rethinking the treatment paradigm for multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26.

309. Hamad N, Ananda-Rajah M, Gilroy N, MacIntyre R, Gottlieb D, Ritchie D, Harrison S, Kennedy G, Watson AM, Greenwood M, Doocey R, Perera T, **Spencer A**, Wong E, O'Brien T, Shaw P, Conyers R,

Milliken S, Bardy P, Larsen S, Ho PJ, Lai H, Bajel A, Butler J, Tiley C, D'Rozario J, Johnston A, Cochrane T, Mills T, Irving I, Pullon H, Purtill D. Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement. *Intern Med J*. 2021 Aug;51(8):1321-1323. doi: 10.1111/imj.15263.

310. Creeper K, Augustson B, Kusel K, Fulham MJ, Ho J, Quach H, Mollee P, Weber N, Talaulikar D, Johnston A, Murphy N, Joshua D, Ward C, Ling S, Gibson J, Szer J, Harrison S, Zannettino A, Jaksic W, Lee C, **Spencer A**, Kalff A, Szabo F, Romeril K, Chan H, Gibbs S, Horvath N, Prince HM. Imaging of patients with multiple myeloma and associated plasma cell disorders: Consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. *Intern Med J.* 2021 Oct;51(10):1707-1712. doi: 10.1111/imj.15457.

311. Claudio C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, **Spencer A,** Sonneveld P, Anderson KC. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. *Frontiers in Oncology* 2022 Feb;12 https://doi.org/10.3389/fonc.2022.820768

312. Reale A, Khong T, **Spencer A.** Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment. J Clin Med 2022; 11(23):6892.

313. Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, **Spencer A**, Ritchie D, Agarwal R, Blombery P. Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. *Intern Med J* 2022; 52(7):1286-1287.

314. Sim S, Kalff A, Tuch G, Mollee P, Ho PJ, Harrison S, Gibbs S, Prince HM, **Spencer A**, Joshua D, Lee C, Ling S, Murphy N, Szabo F, Szer J, Weber N, Ward C, Talaulikar D, Zannettino A, Quach H. The importance of frailty assessment in multiple myeloma; Position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. *Intern Med J* 2023;53(5):819-824.

315. Lim SL, **Spencer A.** Putting the best foot forward when treating newly diagnosed multiple myeloma. *Intern Med J* 2023;53(3):318-322

316. Kazzi C, Kuznetsova V, Siriratnam P, Griffith S, Wong S, Tam CS, Alpitsis R, **Spencer A,** O'Brien T, Malpas CB, Monif M. Cognition following chimeric antigen receptor T-cell therapy: A systematic review. *J Autoimmun* 2023; Oct 12:140:103126.doi: 10.1016/j.jaut.2023.103126.

317. Tan JLC, Barmanray RD, Cirone B, Klarica D, Russell A, **Spencer A**, Wright T. Cardiovascular and metabolic risk incidence among adult allogeneic stem cell transplant recipients: A narrative review. *Transplant Cell Ther* 2024 Jul 23: S2666-6367(24)00545-1

318. Ho PJ, Quach H, Sidiqi MH, Lee CH, Butler J, **Spencer A**, Micklethwaite K, Li J, Cusson E, Bagnall R, Harrison SJ. Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia. Front Oncol 2025; 14: 1535869. Doi: 10.3389/fonc.2024.1535869.

319. van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, **Spencer A**, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C, Popat R, Musto P, Rodriguez-Otero P, Yong K, Rasche L, Terpos E, Raab MS, Boccadoro M, Sonneveld P, Einsele H. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. *Lancet Haematology* 2025; 12(10):e635-649.

320. Wronski M, Wesselingh R, Kazzi C, Seery N, Ko K, Li J, Tan TH, Simpson T, Abbott C, Fleming S, Inam S, Tam CS, Wong SM, O'Brien T, van der Walt A, **Spencer A**, Butzkueven H, Monif M. Neurotoxicity associated with chimeric antigen receptor T-cell therapy. *Journal of Neuroimmunology* 2025; 407:578717

321. Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, **Spencer A**, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. *Journal of Clinical Oncology* 2025; 43(24):2739-2751.

322. Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R, Schjesvold F, Gay F, Manier S, Weisel KC, Kaiser M, van de Donk NWCJ, Zamagni E, Rodriguez-Otero P, Perrot A, Driessen C, Bila J, Laane E, Dytfeld D, Touzeau C, Beksac M, Raab MS, Cavo M, Mohty M, **Spencer A**, Ludwig H, Einsele H, San-Miguel J, Sonneveld P. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. *Nature Reviews Clinical Oncology* 2025; 22(9):680-700.

323. Lim SL, Engelhardt M, Terpos E, Gay F, Van de Donk NWCJ, Einsele H, Sonneveld P, Kaiser M, Boccadoro M, **Spencer A.** European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma. *American Journal of Hem*atology 2025; 100(12):2320-2332.

324. **Spencer A**. New prognostic systems for multiple myeloma in the context of contemporary therapies. *Blood* 2025; 146(13):1546-1549.

325. McCaughan G, Beer H, Bryant C, Ho PJ, King T, Lee C, Mollee P, Prince HM, **Spencer A**, Talaulikar D, Vandyke K, Weber N, Yong A, Harrison S, Quach H. Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. *Internal Medicine Journal* 2025; 55(10):1741-1751.

326. van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, **Spencer A**, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CLBM, Broijl A, Touzeau C, Manier S, Hajek R, Bila J, Seval GC, O'Dwyer M, Ludwig H, Fernandez de Larrea C, Popat R, Musto P, Rodriguez-Otero P, Yong K, Kortüm M, Rasche L, Terpos E, Raab MS, Boccadoro M, Sonneveld P, Einsele H. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. *Hemasphere* 2025; 9(11):e70260

Book Chapters

327. Mithraprabhu S, **Spencer A**. (2018) Analysis of Circulating Tumor DNA. In: Heuck C., Weinhold N. (eds) Multiple Myeloma. Methods in Molecular Biology, vol 1792. Humana Press, New York, NY.

328. Mithraprabhu S, **Spencer A**. (2018) Liquid biopsy in multiple myeloma. http: //dx. doi. org/10 .5772 /intechopen.72652.

329. Reale A, Khong T, Xu R, Savvidou I, Lim S, Carmichael I, Greening DW, **Spencer A**. (2020) Understanding the role of extracellular vesicles in multiple myeloma. In Copland B (ed) Hematologic Malignancies: An Overview. Nova Science Publishers. ISBN: 978-1-53618-124-1

330. Reale A, Khong T, Xu R, Chen M, Mithraprabhu S, Bingham N, **Spencer A,** Greening DW. (2020) Human plasma extracellular vesicle isolation and proteomic characterisation for the optimization of liquid biopsy in multiple myeloma. Meth. Mol. Biol. 2021; 2261: 151-191.

Other Publications

331. Rule SAJ, O'Brien SG, **Spencer A**, Apperley JF, Goldman JM. Bone Marrow Transplantation - Review articles must accurately reflect current practices. *British Medical Journal* 1995; 310, 874.

332. Lincz L, Crooks R, Granter N, Way S, **Spencer A.** Identification of minimal residual disease in PBSC harvests from patients with multiple myeloma using nested PCR. *Proceedings of a workshop on minimal residual disease in leukaemia and lymphoma* Melbourne, August, 1998.

333. **Spencer A,** Roberts A, Bailey M, Schran H, Lynch K. No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group MM6 Trial - Highlights from ASH 2003: Selected abstracts on leukemia and myeloma. *Oncology Review* 2004; 19 (4): 4